PEST-domain enriched tyrosine phosphatase as a positive regulator of mast cell signaling by Menon, Ambili
                                                                                                                                                                 
 
 
PEST-domain enriched tyrosine phosphatase as a 
positive regulator of mast cell signaling 
 
 
Zur Erlangung des akademischen Grades eines 
DOKTORS DER NATURWISSENSCHAFTEN 
(Dr. rer. nat.) 
Fakultät für Chemie und Biowissenschaften 





aus Gujarat, India 
2013 
 
Dekan:  Prof. Dr. Martin Bastmeyer 
Referent:  Prof. Dr. Andrew Cato 
Korreferent: Prof. Dr. Jörg Kämper 
Tag der mündlichen Prüfung:  19 
th
 April 2013 
 
 




Erklärung der Selbstständigkeit 
 
 
Ich erkläre, dass ich diese Dissertation selbstständig angefertig habe. Ich habe nur 
die angegebenen Quellen und Hilfsmittel benutzt und wörtlich oder inhaltlich 




I hereby declare that this dissertation is my own independent work. I have only 
















The work presented in this thesis was performed at the Institue für 
Toxikologie und Genetik (ITG), Karlsruher Institut für Technologie. 
I owe my warmest gratitude to my supervisor Prof. Dr. Andrew Cato for 
his guidance, support, and also for giving me the opportunity to present 
my data on various congresses as well as for his advice at every step of 
my PhD project. 
I express my sincere thanks to Prof. Dr. Jörg Kämper for accepting to 
review my thesis. 
I am also grateful to my TAC committee members PD Dr. Véronique 
Orian-Rousseau and Dr. Thomas Dickmeis for their many helpful inputs 
and discussions. 
I would like to thank PD Dr. Ludger Klein-Hitpass Universitätsklinikum 
Essen for performing the Affymetrix gene expression analysis. 
I would like to thank all members of the lab for the constructive 
discussions and technical support. 
I owe my whole-hearted gratitude towards my parents Rema Menon, 
Ramachandran Menon and brothers Arun and Abhilash, for their 
comprehensive support, for always believing in me, even though you 
don’t really understand what it is that I do. 
Finally, my deepest gratitude to my husband Vipin Madhavan, for his 
never-ending love and support, for sharing all the ups and downs in life, 
and always helping me to look on the brighter side of life. Thanks for 
everything!!!!! 
 







Name   : Ambili Menon 
Date of Birth : 03/19/1983 







Karlsruhe Institute of Technology:     May 2010-present 
Institute of Toxicology & Genetics 
PhD-PEST domain enriched tyrosine phosphatase a positive regulator of mast cell 
signaling 
 
Virginia Commonwealth University, USA:   Aug 2007- June 2008  
Biochemistry Course 
 
Maharaja Sayajirao University, India:    2004-2006                                                                                    
Master of Science in Microbiology 
Grade:  A   (First class) 
 
 
Maharaja Sayajirao University, India:    2001-2004                                              
Bachelor of Science Zoology as major                                                   
Botany& Chemistry as secondary 
Grade:  A   (First class)                                                         
               
 
Gujarat Refinery English Medium School :   2001 




Vidya Vihar English Medium School:    1999                                
Secondary School Certificate (SSC) 
Grade: Distinction-84.86%                      





Karlsruhe Institute of Technology, Germany:   May2010-present 
PhD work in the laboratory of Prof. Andrew Cato in the Institute of toxicology & 
Genetics,  
Thesis- PEST domain enriched tyrosine phosphatase is a positive regulator of mast 
cell signaling 
 
Virginia Commonwealth University, USA :   Jan 2008-April2008 
Worked in the laboratory of Dr. Charles Chalfant in the Department of 
Biochemistry, Study of translocation of cPLA2α mediated by the N-terminal C2 
domain in response to various inflammatory agonist 
 
Virginia Commonwealth University, USA :   Sep2007-Dec2007 
Worked in the laboratory of Dr. Robert Diegelmann in the Department of 
Biochemistry,  
Novel Strategy Employing Protein Synthesis Inhibition to Reduce Neutrophil 
Extravasations following Tissue Injury and could form a basis could form a basis 
for a therapy to prevent ARDS” -An in Vitro Study 
 
Maharaja Sayajirao University, India:    Aug2004-April2006 
Master student in the laboratory of Dr.Anuradha Nerurkar in Department of 
Microbiology,  
Master Thesis: Strain improvement of Aspergillus niger Aj2k for increased 





Obiri, D.D., Flink, N., Maier, J.V., Neeb, A., Maddalo, D., Thiele, W., Menon, A., 
Stassen, M., Kulkarni, R.A., Garabedian, M.J., et al. (2011). PEST-domain-
enriched tyrosine phosphatase and glucocorticoids as regulators of anaphylaxis in 
mice. Allergy. 
 
He, Y; Liu, S; Menon, A; Stanford, S; Oppong, E; Gunawan, A; Wu, L; Wu, D; 
Barrios, A; Bottini, N; Cato, A; Zhang, Z (2013).A potent and selective small 
molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a 
paramount target associated with autoimmune diseases. Journal of Medicinal 
Chemistry.  (submitted, under review). 
 
                                                                                                                                                                 
 
 
Menon, A., Neeb, A., Stassen, M., Kleiien-Hitpass, L., Obiri, D., Oppong, E., 
Barrios, A.,  Yantao, H., Zhang, Z., Cato,A (2013) Allergen-mediated association of 





PEST- domain enriched tyrosine phosphatase-Role in mast cell signaling. 
Summer School on Mast Cell Biology of the DFG SPP 1394 
"Mast Cells - Promoters of Health and Modulators of Disease" Institute of 
Immunology  
Medical Faculty Carl Gustav- 
June 2012, Dresden 
 
PEST domain enriched tyrosine phosphatase (PEP) is a positive regulator of 
anaphylaxis in mice 
Arbeitsgemeinschaft Mastzellen und Basophile der ADF (Arbeitsgemeinschaft 
Dermatologische Forschung) mit unterstuetzung der DGAKI (Deutschen 
Gesellschaft fur Allergologie und klinische Immunologie. 




PEST-domain-enriched tyrosine phosphatase (PEP): Modulator of Mast Cell 
Signaling  
EMBRN-COST International Mast cell and Basophil Meeting hosted by the EU 
COST Action BM1007 "Mast cells and basophils", the European Mast Cell & 
Basophil Research Network November 2012, Berlin 
 
PEST Domain-Enriched Tyrosine Phosphatase (PEP) Positively Regulates 
Anaphylaxis 









                                                                                                                                                                 
 
 
Strain improvement of Aspergillus niger Aj2k for increased endopectinase 
production 
Indian Science Academy sponsored seminar on Modern Biology:  Facets and 
Prospects organized by Tata Institute of Fundamental Research, Mumbai and 
Department of Biochemistry,  
Maharaja Sayajirao University of Baroda-  
October 2005, Baroda India 
 
Workshops & symposium attended 
 
Summer School on Mast Cell Biology of the DFG SPP 1394 
"Mast Cells - Promoters of Health and Modulators of Disease" Institute of 
Immunology  
Medical Faculty Carl Gustav June 2012-Dresden 
 
DST (Department of Science and Technology Govt of India) sponsored workshop 
on the modern techniques in molecular biology, genetics and microbial 
diversity.2005 
 
Attended an international symposium on ‘Emerging trends in drug discovery’ 



















PEST-domain enriched tyrosine phosphatase (PEP) is one of three intracellular 
phosphatases that belong to the PEST (proline, glutamic acid, serine, threonine-
rich) group of the non-receptor protein tyrosine phosphatases (PTPs). PEP is a 
potent negative regulator of T-cell receptor signaling, which acts by suppressing 
the activity of Src-like family of receptor tyrosine kinases. PEP is also expressed in 
mast cell and has been identified as positive regulator of antigen-mediated 
anaphylaxis, but its mode of action is not known. To assess the action of PEP in 
mast cells, bone marrow derived mast cells (BMMC) from mice with genetic 
ablation of this gene was used. In co-immunoprecipitation experiments using 
PEP+/+ and PEP-/- BMMC, PEP was shown to interact with the early signaling 
components of mast cells such as Csk and Lyn. Sucrose density gradient 
centrifugation studies showed that in the absence of IgE receptor crosslinking, PEP 
is present in soluble fractions but migrates to lipid rafts along with Csk upon IgE 
crosslinking in PEP+/+ BMMC.  In PEP-/- BMMC, Csk is already present in the 
lipid rafts in the absence of antigen stimulation but further accumulates in this 
fraction following IgE receptor crosslinking. In the lipid rafts, PEP was found to 
interact with Cbp/PAG and thereby leads to dephosphorylation of Cbp/PAG and 
reduced recruitment of Csk into the lipid rafts. As Csk negatively regulates the 
activity of Lyn, the reduced recruitment of Csk to the lipid rafts positively 
regulates the activation of Lyn. BMMC from PEP-/- mice have reduced Lyn 
activity and downstream signaling cascades including a reduced NFAT activity 
and degranulation upon IgE receptor crosslinking. Overexpression of PEP in the 
PEP-/- BMMC rescued NFAT activity and restored degranulation. Furthermore 
treatment of  PEP+/+ BMMC with L75N04, a compound with a bicyclic 
benzofuran salicylic acid core mimicked all the signaling defect seen in PEP-/- 
                                                                                                                                                                 
 
 
BMMC including a reduced NFAT activity and degranulation. Gene expression 
profile showed that cytokine genes that are regulated by Ca
2+
/NFAT pathway are 
down-regulated by the absence of PEP or by the chemical inhibition of PEP 
activity by compound L75N04. The negative regulation of degranulation by the 
absence of PEP or by the compound L75N04 leads to inhibition of passive 
systemic anaphylaxis in mice. These findings together provide mechanistic 
explanations for the action of PEP as an important positive regulator of 






























Die PEST-domänenreiche Tyrosinphosphatase PEP ist eine von drei intrazellulären 
Phosphatasen der Gruppe der prolin-, glutamin-, serin- und threoninreichen 
Proteintyrosinphosphatasen (PTP). PEP unterdrückt die Aktivität von Mitgliedern 
der Familie Src-ähnlichener Rezeptortyrosinkinasen und hemmt auf diese Weise 
den T-Zellrezeptorsginalweg. PEP ist auch in Mastzellen exprimiert, in denen es 
die antigenvermittelte anaphylaktische Reaktion verstärkt. Die molekulare 
Wirkweise von PEP in Mastzellen war bislang nicht bekannt. Um die Rolle von 
PEP in Matzellen zu untersuchen, wurden Mastzellen aus dem Knochnmark (bone 
marrow derived mast cells -BMMC) von Mäusen mit einer genetischen Ablation 
von PEP herangezogen. In Koimmunopräzipitationsexperimenten unter 
Verwendung von BMMC aus wildtype (PEP+/+) und(PEP-/-) Mäusen konnte 
gezeigt werden, dass PEP mit frühen Komponenten der Mastzellsignalkaskade wie 
Csk und Lyn interagiert. In Analysen von Zellfraktionierungen nach Zentrifugation 
über einen Sukrosedichtegradienten konnte nachgewiesen werden, dass PEP in 
ruhenden Wildtyp-BMMCs in den löslichen Fraktionen lokalisiert ist, während es 
nach IgE-Rezeptor-Quervernetzung gemeinsam mit Csk in spezialisierte 
Membranbereiche, den sogenannten‘Lipid Rafts transloziert. In PEP -/- BMMC 
befindet sich Csk bereits vor der Aktivierung in der Lipid Raft-Fraktion und wird 
nach IgE-Rezeptor-Quervernetzung weiter angereichert. Innerhalb der Lipid Raft-
Fraktion konnte die Interaktion von PEP mit Cbp/PAG gezeigt werden, diese führt 
zur Dephosphorylierung von Csk und in Folge zur verminderten Rekrutierung des 
Proteins in die Lipid Rafts. Da Csk die Aktivität von Lyn hemmt, verstärkt die 
reduzierte Rekrutierung von Csk in die Lipid Rafts auch die Aktivierung von Lyn. 
BMMC von PEP-/- Mäusen zeigen reduzierte Lyn-Aktivität und damit auch eine 
verminderte Aktivierung von nachgeordneten Ereignissen wie der NFAT Aktivität 
                                                                                                                                                                 
 
 
und verminderter Degranulierung nach IgE-Rezeptor-Quervernetzung. In rescue-
Experimenten konnte die NFAT-Aktivität in PEP-/- BMMC und die 
Degranulierung durch Überexpression von PEP wiederhergestellt werden. 
Ähnliche Effekte wie sie in PEP-/- BMMC in Bezug auf die NFAT-Aktivität und 
Degranulierung beobachtet wurden, konnten in PEP+/+ BMMC nach Behandlung 
mit L75N04, einem Wirkstoff mit einem bizyklischen Benzfuronsalicylsäurekern, 
beobachtet werden. Genexpressionsprofile zeigten, dass die Abwesenheit von PEP 
in BMMC wie auch die Behandlung von Wildtyp BMMCs mit L75N04 die 
Expression von durch den Ca
2+/
NFAT-Signalweg regulierten Zytokinen reduziert. 
Die Hemmung der Degranulierung in Folge von PEP-Elimination oder L75N04-
Behandlung resultierte konsequenterweise in der Inhibierung der passiven 
systemischen Anaphylaxis in Mäusen. Diese Befunde liefern einen wichtigen und 
grundlegenden Erklärungsansatz für die Wirkweise von PEP als Schüsselprotein 
















bp   base pair 
CCL-2 chemokine (C-C motif) ligand 2 
CCL-12 chemokine (C-C motif) ligand 12  
CO2   carbon-di-oxide  
DNA deoxy-ribonucleic acid 
dNTP deoxynucleoside triphosphate 
EDTA Ethlenediamine-N,N-tetraacetic acid 
FcεRI high affinity IgE receptor 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GM1 (monosialotetrahexosylganglioside) 
h hour 
HEPES N-2hydroxyethilpiperasine-n’-2-ethansulfonic acid 
HRP horseradish peroxidase 
HRH4 histamine H4 receptor 
HSP60 heat shock protein 60 
IBD inflammatory bowel disease 
IBS irritable bowel syndrome 
IgE immunoglobulin E 
IFN interferon 
IL interleukin 
                                                                                                                                                                 
 
 
ITAM immunoreceptor tyrosine-based activation motif 
LPS lipopolysaccharide 





mRNA messenger RNA 
PBS phosphate buffered saline 
PCR polymerase chain reaction  
RT room temperature 
S.E.M standard error of mean 
SCF stem cell factor 
TNF-α tumor necrosis factor α 
Th T helper 
TLR Toll-like receptor 
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Several studies suggest that the prevalence of allergic diseases has increased 
significantly over the past 20-30 years, a trend that shows no sign of abating. It is 
estimated that more than 80 million people in Europe suffer from some kind of 
allergic diseases such as allergic rhinitis, allergic conjunctivitis, food allergy, 
atopic dermatitis, and asthma and that by 2015 half of all Europeans will be 
suffering from an allergy. The rise in prevalence also has socio-economic impact, 
as 70 % of patients state their social and physical activity is limited and it also adds 
burden to health care cost as it is estimated that asthma alone costs Europe €27 
billion per year, with expenditure expected to grow to €50 billion within a decade 
(www.efanet.org/allergy) (European Academy of Allergology and Clinical 
Immunology (EAACI) Position paper, 2006). 
The spreading epidemic of allergy and asthma has heightened the interest in mast 
cells, which remain at the core of our understanding of allergic responses as they 
contribute in the elicitation and subsequent release of potent inflammatory 
mediators that lead to allergic reaction. As a result they are one of the major targets 
of investigations and therapeutic interventions in allergy (Nauta et al., 2008). 
1.1Mast cell biology 
Origin and Development 
Mast cells were first described by Paul Ehrlich in the late 19th century based on the 
metachromatic staining properties of large cytoplasmic granules (Ehrlich, 1878). 
The “well-fed appearance” led him to designate these cells as mast cells. Today we 
know that the granule content does not originate from an uptake but from the 
                                                                                                                                                                Introduction 
2 
 
synthesis and storage of high amounts of proteoglycans, proteases and other 
mediators. Mast cells are key components of innate and adaptive immune system. 
The essential role they play in the immune system is reflected by the fact that no 
human individual has been identified until today who lacks mast cells (Stevens and 
Adachi, 2007). Mast cells are involved in the inflammatory response through the 
combined activities of a variety of cell surface receptors, the important one being 
the high affinity IgE receptor, FcεRI (Gilfillan and Tkaczyk, 2006). The activation 
of these receptors on mast cells allows them to be involved in the immune 
responses to bacterial, viral and parasitic infections (Dawicki and Marshall, 2007).  
Mast cells originate from multipotent hematopoietic stem cell precursors in the 
bone marrow. These multipotent progenitors (MPPs) get differentiated to 
committed mast cell progenitors (MCPs) in the bone marrow and are then  released 
into the bloodstream and circulate until they extravasate into the connective tissue 
and serosal/mucosal cavities throughout the body (Okayama and Kawakami, 
2006). Upon arrival at peripheral tissues, the committed mast cell progenitors 
develop into mature mucosal or connective tissue mast cells in response to factors 
released by the local tissue (Okayama and Kawakami, 2006). The development of 
MCPs to mature mast cells is strongly dependent on the microenvironment and, 
thus, on the production of growth factors at the site of differentiation. The cardinal 
factor for mast cell growth, differentiation, proliferation and survival is the stem 
cell factor (SCF) that binds to the receptor tyrosine kinase c-Kit and is expressed 
by stromal cells as a soluble or a membrane bound molecule in various tissues. 
Mast cells deprived of SCF undergo apoptosis (Galli et al., 1994; Longley et al., 
1997; Okayama and Kawakami, 2006). Several other cytokines also participate in 
the regulation of mast cell proliferation and development under in vitro conditions 
(Okayama and Kawakami, 2006). The first cytokine identified to drive in vitro 
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mast cell growth and development is Interleukin-3 (IL-3). This cytokine is able to 
independently promote the differentiation of murine hematopoietic stem cells into 
mucosal type BMMCs and is sufficient to support the growth and survival of the 
resulting culture (Ihle et al., 1983; Razin et al., 1984). In contrast to SCF, IL-3 is 
dispensable for in vivo mast cell development and proliferation, as IL-3 knockout 
mice exhibit no reduction in the number of mast cells in their tissues (Lantz et al., 
1998). Furthermore, human mast cells do not express the IL-3 receptor and thus do 
not respond to this cytokine (Valent et al., 1990). 
Two types of mast cells (mucosal and connective tissue type) can be differentiated 
by their tissue of residence and by their differential histological staining properties 
and the proteases they contain within their secretory granules. Mucosal mast cells 
are present in mucosal epithelial tissues of the intestine and lungs, while 
connective tissue mast cells are present in the peritoneal cavity and skin (Hallgren 
and Gurish, 2007). Mucosal mast cells do not stain with the histological stain 
safranin and predominantly express mouse mast cell protease (mMCP-1) and 
(mMCP-2). Connective tissue mast cells stain positively with safranin as a result of 
heparin being contained within their granules and they express mMCP-3, mMCP-
4, mMCP-5 and mMCP-6 (Beil et al., 2000; Gurish et al., 1992). 
1.2 Mast cell activation  
Stimulation of the mast cell activation, initiated either by interaction of the antigen 
specific antibodies or the antigen with the corresponding mast cell receptors, is 
referred to as immunologic activation. Alternatively, the stimulation induced by 
substances such as neuropeptides or cytokines is termed as non-immunological 
activation. Both immunological and non-immunological stimulation can elicit 
distinct, although sometimes overlapping patterns of mediator secretion and 
degranulation as seen in Fig 1.0 






Fig 1.0 Different ways of mast cell activation – A scheme illustrating multiple receptors that are 
displayed on the mast cells surface. Mast cells express tetrameric high affinity receptor for IgE (FcεRI), interferon 
gamma (IFN‐γ) primed mast cells express FcγRIII, who’s cross‐linking can induce the release of mediators. These 
cells also express Toll‐like receptor 2 (TLR2), TLR3, TLR4, TLR5, TLR6, TLR7, and TLR9 as well as complement 
component receptors like C3aR, C5aR.  
The classical way of activating mast cells, especially in allergic reactions, is 
through their high affinity IgE receptors, FcεRI. Apart from activation via FcεRI, 
they also release mediators following aggregation of low affinity IgG (FcγRIII) 
receptors (Katz et al., 1992). Mast cells also express multiple receptors for 
complement components (anaphylatoxins) C3a, C4a and C5a. The complement 
system is involved in a number of processes contributing to host defense and/or 
inflammation (Mousli et al., 1994). Mast cells can be activated by different 
bacterial components through their interactions with toll-like receptors (TLRs) 
expressed on the mast cell surface (Medzhitov et al., 1997).The mast cell-
activating neuropeptides include substance P, calcitonin gene regulated peptide, 
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vasoactive intestinal peptide and neurotensin (Church et al., 1991). Mast cells can 
also be activated by different types of cytokines and chemokines, such as 
macrophage inflammatory protein 1α (MIP-1α) and monocyte chemoattractant-1 
(Alam et al., 1994). Other compounds that can directly activate mast cells include 
calcium ionophores, compound 48/80 (a histamine-releasing agent, its mechanism 
of action is commonly attributed to a direct, receptor-bypassing property to 
activate the G(i/o) class of G proteins), synthetic adrenocorticotropic hormone, 
adenosine and endothelin (Metcalfe et al., 1997). 
1.3 FcεRI-mediated mast cell activation 
FcεRI-The high affinity receptor for IgE  
The classical route of mast cell activation is through the adaptive immune response 
via antibodies that bind to receptors on the mast cell surface. This is how mast cells 
act both in the immune defense towards parasites and in mediating hypersensitivity 
reactions such as allergies and asthma. 
Antigen-dependent mast cell activation is regulated by a complex series of 
intracellular signaling processes which is initiated following FcεRI aggregation. 
FcεRI is a tetrameric receptor that comprises, α-chain (IgE, binding subunit), as 
well as a tetra membrane spanning β-chain and a homo-dimeric di-sulphide-linked 
γ-chain (Fig 1.1) (Kinet, 1999). 
The FcεRIα chain is an N-glycosylated type I integral membrane protein which is 
heavily glycosylated and contains the binding site for the constant region (Fc) of 
IgE. The assembly, folding and core glycosylation of the immature FcεRIα variant 
takes place in the endoplasmic reticulum (ER). The homodimeric γ-chain subunit 
masks the ER-retention signals and thereby enables the export of the FcεRI 
complex from the ER to the cell surface (Fiebiger et al., 2005; Letourneur et al., 
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1995; Ra et al., 1989; Shimizu et al., 1988). When the β chain and γ chain are 
absent, the immature FcεRIα variant is trapped in the ER by a retention signal. 
The FcεRIβ chain amplifies FcεRI signal transduction. It contains an immuno 
receptor tyrosine-based activation motif (ITAM). β chain does not induce signal 
transduction by itself rather it amplifies signal-transduction induced by enhancing 
the phosphorylation of the ITAMs of the γ-chains (Donnadieu et al., 2000; 
Kurosaki et al., 1992). 
The γ-chain dimer is a disulfide-linked homodimer and is shared by various Fc 
receptors. Each of the FcεRIγ chains consists of a short extracellular and trans-
membrane region and a cytoplasmic domain which carries an ITAM. These 
ITAMs are essential for FcεRI-mediated signal transduction involved in mast cell 
activation and survival (Ravetch and Kinet, 1991; Sakurai et al., 2004).  
 
Fig 1.1 Domains of monomeric FcεRI- The high affinity IgE receptor consists of α, β-subunit and a γ 
dimer. FcεRI activation is initiated by receptor aggregation, which occurs as a result of several IgE molecules 
binding to a single multivalent antigen molecule. Adapted from (Rivera and Gilfillan, 2006) 
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The presence of IgE antibodies induces enhanced surface expression levels of 
FcεRI in vitro and in vivo. IgE-mediated up-regulation of FcεRI is a complex 
process involving stabilization of FcεRI on the cell surface by IgE-binding and 
usage of a receptor pool derived from recycled and newly synthesized FcεRI 
combined with a continued basal level of protein synthesis (Borkowski et al., 2001; 
Novak et al., 2001; Yamaguchi et al., 1997)  
IgE mediated FcεRI signaling 
To initiate mast cells activation through FcεRI, IgE antibodies that are bound to 
FcεRI are cross-linked by the cognate multivalent antigen (allergen). Cross-linkage 
of IgE by the interaction of allergen with the FcεRI receptors on the surface of 
mast cells brings the receptors into juxtaposition and initiates mast cell activation. 
After aggregation, FcεRI coalesces with specialized microdomains of the plasma 
membrane known as lipid rafts which are glycolipid-enriched membrane domains 
(Brown and London, 1998; Field et al., 1999), allowing phosphorylation of 
tyrosine residues within the ITAM sequences YXXL/I (a tyrosine separated from a 
leucine or isoleucine by any two other amino acids, giving the signature motif 
YxxL/I) present in the receptor subunits (Pribluda et al., 1994) by the Src kinase 
Lyn which is potentially activated within these microdomains. When 
phosphorylated, the β- and γ-chain ITAMs provide high affinity docking sites for 
the SH2 domains of Lyn and Syk (Benhamou et al., 1993; Chen et al., 1996; 
Jouvin et al., 1994).   
The tethering of Syk to the phosphorylated ITAMs of the γ-chain leads to 
phosphorylation of Syk at its catalytic domain thereby increasing its catalytic 
activity which is essential for IgE mediated mast cell signaling (Benhamou et al., 
1993; Benhamou and Siraganian, 1992; Costello et al., 1996). For coordination of 
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the downstream signaling subsequent phosphorylation of adaptor molecule LAT 
(linker for activation of T-cells) is important (Saitoh et al., 2000).  
LAT resides mainly in lipid rafts owing to its juxtamembrane palmitoylation site 
(Zhang et al., 1998; Zhu et al., 2005). LAT phosphorylation leads to recruitment 
and binding of several adaptor molecules such as GRB2 (growth factor-receptor-
bound protein 2), GADS (GRB2-related adaptor protein), SHC (SH2-
domaincontaining transforming protein C), and SLP76 (SH2-domain-containing 
leukocyte protein of 65k Da), the guanine-nucleotide exchange factors SOS (son of 
seven less homologue) and VAV and the signaling enzymes phospholipaseCγ 
(PLCγ). PLCγ hydrolyses the membrane phospholipid (phosphatidylinositol-5-
bisphosphate) to form InsP3 (inositol 3, 4, 5-triphosphate) and DAG 
(diacylglycerol) (Gilfillan and Tkaczyk, 2006) as shown in Fig 1.2. 
A complementary activation pathway involves the Fyn-GAB2-PI3K axis. 
Activation of Fyn results in phosphorylation of GAB2. This leads to the binding of 
PI3K (phosphatidylinositol 3-OH kinase) and subsequently activation of Btk 
(Bruton’s tyrosine kinase). Rac as well as Btk and Syk are able to activate 
phospholipaseCγ (PLCγ) leading to formation of inositol triphosphate (IP3) and 
diacylglycerol (DAG) (Parravicini et al., 2002). 
Formation of IP3 leads to calcium depletion of the endoplasmic reticulum (ER) 
which originates from activation of IP3-receptors. IP3-receptors are transmitter-
regulated cation channels of the ER and activation results in calcium release from 
the ER and an increase of cytosolic calcium. The resulting depletion of the 
intracellular stores induces calcium entry through the plasma membrane via CRAC 
(calcium release activated calcium) channels by activation of Orai1 or CRAM1- a 
plasma membrane protein and the pore forming subunit of (CRAC) channel. This 
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calcium depletion from ER also leads to translocation of the stromal interaction 
molecule 1 (Stim1) under the plasma membrane. Stim1 is a Ca
2+
 sensor that 
activates CRAC channels and migrates from the Ca
2+
 store (ER) to the plasma 
membrane. After translocation, Stim1 interacts with Orai1, resulting in activation 
of the CRAC channel and calcium-influx. This increase in intracellular calcium 
induces degranulation of mast cells (Chang et al., 2008; Metcalfe et al., 2009; 
Mignen et al., 2007). 
In contrast, SLP-76, SHC, GRB2, VAV and SOS are involved in the activation of 
small GTPases such as Ras. These GTPases further activate members of the 
mitogen-activated protein kinase (MAPK) family such as ERK (extracellular 
signal-regulated kinase), JNK (c-Jun N-terminal kinase), and p38 resulting in 
synthesis of eicosanoids, chemokines and cytokines (Siraganian, 2003). 
Thus FcεRI-mediated mast cell activation results in a complex signaling cascade 
which induces mast cell degranulation and de novo synthesis of pro-inflammatory 











Fig 1.2 The signaling cascade in activated mast cells - Aggregation of FcεRI leads to a Lyn and Syk-
dependent phosphorylation of LAT resulting in recruitment and binding of the adaptor molecules GRB2, GADS, 
SHC, and SLP76, the guanine-nucleotide exchange factors SOS and VAV and the signaling enzymes PLCγ. In 
parallel, PI3K is activated by Fyn which leads to Btk-PLCγ axis. PLCγ is involved in induction of calcium flux and 
cellular degranulation whereas the guanine-nucleotide exchange factors promote the induction of the MAPK 
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Kit Receptor Activation Potentiates FcεRI Signaling 
Since mast cells respond to multiple signals simultaneously in vivo, it was thought 
that cross-talk must exist among the key signaling pathways. SCF/c-Kit (Stem cell 
factor) receptor activation has been shown to cross-talk with the FcεRI signaling 
cascade, acting to enhance the FcεRI mediated release of histamine and LTC4 
(Bischoff and Dahinden, 1992) through synergistic activation of PLCγ, the 
MAPKs, and Akt (Hundley et al., 2004) 
SCF-receptor is a member of the type III receptor tyrosine kinase family encoded 
by the proto-oncogene, c-kit. It bears five immunoglobulin-like extracellular 
domains and no ITAM. Unlike FcεRI, SCF-receptor is a single-chain receptor that 
has inherent protein-tyrosine-kinase activity (Fig 1.3). Binding of SCF results in 
receptor dimerization and auto phosphorylation (Galli et al., 1993; Zhang et al., 
2000). 
 
Fig 1.3 Schematic drawing of a SCF-c-KIT receptor complex- The structure of c-Kit receptor is 
characterized by an extracellular ligand-binding region containing five immunoglobulin-like repeats, a trans- 
membrane sequence, an auto-inhibitory juxtamembrane domain and two intracellular tyrosine kinase domains: an 
ATP-binding pocket and a kinase activation loop. Adapted from (Blechman et al., 1995; Chan et al., 2003; 
Roskoski, 2005) 




Tyrosyl-phosphorylated c-Kit recruits signaling molecules containing the Src 
homology 2 (SH2) domains, such as phosphatidylinositol (PI)-3 kinase, 
phospholipase Cγ1, Grb2, and the Src kinase, to c-Kit and initiates cytoplasmic 
signaling. Actin reorganization and the release of Ca
2+
 are triggered, and kinases 
such as the mitogen-activated protein kinase (MAPK) kinase MEK and its 
substrates ERK1 and ERK2, as well as survival factors such as Akt/PKB, are 
activated (Fig 1.4). Thus, a complex set of signaling pathways is activated in mast 
cells through c-kit stimulation, and not all factors involved in these pathways have 
been elucidated (Galli et al., 1993; Galli et al., 1994). 
 
 
Fig 1.4 SCF-c-Kit receptor mediated mast cell signaling- Stem-cell factor (SCF)-mediated 
dimerization of KIT induces auto phosphorylation at multiple tyrosine residues in the cytoplasmic tail, resulting in 
the recruitment of various molecules, including the following: cytosolic adaptor molecules, such as SOS; SRC-
family kinases; and signaling enzymes such as phospholipaseCγ (PLCγ) and phosphatidylinositol 3-kinase (PI3K). 
Subsequent activation of these signaling enzymes, as well as the RAS–RAF–mitogen-activated protein kinase 
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(MAPK) pathway leads to mast-cell growth, differentiation, survival, and chemotaxis and cytokine production. 
Adapted from (Gilfillan and Tkaczyk, 2006)  
Signaling through c-kit is essential for mast cell development, as well as for other 
processes in hematopoiesis, erythropoiesis, melanogenesis, and gametogenesis. 
Mice completely deficient in c-kit or its ligand stem cell factor die during 
embryogenesis or neonatally of severe anemia. The addition of SCF to cultured 
mast cells stimulates proliferation, maturation, secretion, cytoskeletal actin 
rearrangements, membrane ruffling, migration, and cell survival (Galli et al., 1993; 
Taylor et al., 1995). 
1.4 Mast cell functions 
Mast cells exert their biological functions exclusively by humoral immune 
mechanism. They exhibit an array of immune-response receptors, adhesion and 
other surface molecules and also release huge amount of diverse biologically active 
mediators which can be divided into two categories (I) preformed mediators such 
as histamine, proteoglycans and neural proteases and certain cytokines like TNF-α, 
(II) mediators that are newly synthesized following activation like chemokines, 
lipid mediators, growth and angiogenic factors which can lead to various pro-
inflammatory, anti-inflammatory and/or immuno regulatory effects (Galli et al., 
2005; Grimbaldeston et al., 2006; Maurer et al., 2003). These biological 
characteristics and their strategic location at sites that interface with external 
environment, closely associated with nerves and blood vessels (Dawicki and 
Marshall, 2007) explains how mast cells can be involved in so many different 
physiological and pathological conditions as seen in Fig 1.5. 
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Innate-immune response to Pathogens 
Mast cells are equipped with a multitude of receptors serving directly or indirectly 
as sensors of pathogen invasion. Many of these belong to the large family of 
pattern recognition receptors (PRR) that bind directly to pathogen associated 
molecular patterns (PAMPs) which are highly conserved sequences (Yarovinsky et 
al., 2006) present in exogenously derived molecules which originate from either 
bacteria or viruses (Anderson, 2000).  
Toll-like receptors (TLR) are an important group of the PRR family. Specifically, 
it has been shown that BMMCs express TLR2, TLR4, TLR6 and TLR8. Through 
TLR-mediated recognition of exogenous particles, mast cells are involved in the 
immune response to bacterial, viral and parasitic infections and function to regulate 
the local tissue immune response to infection by releasing a combination of pre-
formed and newly synthesized inflammatory mediators (Dawicki and Marshall, 
2007). TLR4 expressed on the surface of mast cells allows mast cell activation in 
response to stimulation with the major components of bacterial cells walls- the 
gram negative bacterial component lipopolysaccharide (LPS), and the gram 
positive derived peptidoglycan (Anderson, 2000). Mast cell activation in reaction 
to viral products can be mediated by TLR3, TLR7 and TLR8, and serves to initiate 
the secretion of IL-1β, IL-6, macrophage inflammatory protein (MIP-1α) and 
(MIP-1β) (King et al., 2000).  
Mast cells also play key protective roles in the immune response elicited against 
parasitic infection, including nematodes, and gastrointestinal helminth. This 
response is dependent on secreted mast cell proteases, including MCP-1(Lawrence 
et al., 2004) and MCP-9 (McDermott et al., 2003) for nematodes and 
gastrointestinal helminth. In addition, mast cells also have a protective role in 
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sepsis (Mallen-St Clair et al., 2004) and in response to exposure to bee and snake 
venoms (Rivera, 2006). 
 
 
Fig 1.5 Mast cell activation leads to physiological and pathological effects- A hypothetical model 
for the function of mast cells as pro inflammatory and anti-inflammatory cells. Mast cells are important components 
of the immune system, essential to fight viruses, bacteria, parasites and other invaders at portals of entry of our 
bodies as well as for angiogenesis, and immune tolerance. In allergic reactions mast cells can produce havoc with 
the release of their granules which cause problems ranging from swelling, itching, all the way to lethal anaphylactic 
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shock. They are also involved in auto-immune inflammatory diseases where they seem to have a detrimental role to 
play. 
Physiological processes 
Mast cells play a positive role in non-inflammatory processes such as immune 
tolerance, angiogenesis and tissue remodeling during wound healing (Henz, 2008). 
Angiogenic role for  mast cells is suspected because of their proximity to blood 
and lymphatic vessels and their tendency to accumulate in polyps, tumors, and 
other tissues associated with angiogenesis, and their production of VEGF (vascular 
endothelial growth factor), TGF-β, TNF-α, histamine and heparin all of which have 
demonstrated angiogenic activity (Crivellato et al., 2004). Mast cells control all 
phases of healing from the initial inflammatory response to re-epithelialization and 
tissue remodeling (Noli and Miolo, 2001). 
Mast cell dysregulation and diseases -Pathological effects 
Mast cell activation also has detrimental effects which extend to various 
autoimmune diseases, allergy and asthma.  
In allergic hypersensitivity reactions, dysregulation of the levels of T helper (Th) 2 
cells produced in response to allergen stimulation results in the hyper secretion of 
IgE by B cells. This elevated level of circulating IgE causes an increased rate of 
mast cell activation upon subsequent exposure to the original antigen, which 
results in an exaggerated mast cell IgE/FcεRI mediated inflammatory response 
(Montero Vega, 2006). Severe type I hypersensitivity allergic reaction is the 
anaphylactic shock caused due to increased release of large quantities of 
immunological mediators leading to systemic vasodilation (associated with a 
sudden drop in blood pressure and hypothermia in mice) and edema of bronchial 
mucosa resulting in bronchoconstriction which ultimately lead to death. 
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Mast cells release PGD2 (Prostaglandin D2), LTC4 (Leukotriene C4) and 
histamine; these mediators produce many of the symptoms seen in asthma, 
including mucous secretion, edema of mucosal tissues, and bronchoconstriction. 
Furthermore, asthmatics show indications of chronic activation of these pathways 
as well as abnormal accumulation of mast cells in airway smooth muscle tissue 
(Bradding et al., 2006). 
Mast cells have been shown to play a role in the pathogenesis of Rheumatoid 
arthritis (RA) and Multiple sclerosis (MS). They accumulate in arthritic synovial 
fluid (Nigrovic and Lee, 2007) while in case of MS they accumulate in the lesions 
of brain and the cerebral spinal fluid of patients show high levels of histamine and 
tryptase. Mast cell degranulate in response to myelin basic protein leading to 
increased permeability of the blood brain barrier that occurs in early stages of MS 
(Johnson et al., 1988; Zhuang et al., 1996).  
Mast cells are also involved in the development of atherosclerosis, a cardiovascular 
disorder considered to be a chronic inflammatory disease. Since heart is one of the 
organs rich in mast cells, the mediators released by mast cells after activation are 
believed to be involved in in the development of atherosclerosis and vascular 
aneurysm  formation (abnormal widening of artery). Moreover it is seen that mast 
cells reside in the perivascular tissue of healthy arteries and during the progression 
of atherosclerosis, the cells accumulate in the adventitia and the shoulder region of 
the atherosclerotic plaque(plaques formed within the arteries) (Libby, 2002). 
Increased populations of mast cells are found in tumors such as mammary 
adenocarcinomas, basal cell carcinomas, melanomas, and neurofibromatosis. Mast 
cells can promote mammary tumor development by: (1) disturbing the normal 
stroma-epithelium communication, has been shown in matrix degradation at sites 
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of tumor invasion in rat mammary adenocarcinoma, (2) facilitating tumor 
angiogenesis, and (3) releasing growth factors such as stem cell factor (SCF) and 
nerve growth factor (NGF) that permit the formation of new blood vessels and 
metastases (Theoharides and Conti, 2004). 
Thus these cells have a key role in both induction and elicitation of several chronic 
inflammatory and autoimmune diseases. 
Manifestation of these mast cell driven response are mainly the consequence of the 
release of pro-inflammatory mediators following antigen induced aggregation of 
IgE-bound high affinity receptors (FcεRI) and subsequent phosphorylation of Src 
family kinases (SFKs). Regulated tyrosine phosphorylation of these SFKs is 
required for appropriate cellular response, and this is achieved by protein tyrosine 
phosphatases (PTPs). The equilibrium between these SFKs and PTPs define the 
signal threshold for a given response and is critical for normal immune cell 
development and function. Any dysregulation in this equilibrium can have 
pathological consequences resulting in immunodeficiency, autoimmunity and 
malignancy as stated above in the section on mast cell function. 
1.5 Protein Tyrosine Phosphatase (PTPs) in mast cell signaling 
Protein tyrosine phosphatases play important role in many pathological situations 
and also in the regulation of immune cell functions. PTPases family constitutes a 
large, structurally diverse family of receptor-like and cytoplasmic enzymes which 
is expressed in all eukaryotes. There are ∼100 PTPase genes encoded within the 
human genome. Every PTPase is composed of at least one conserved domain 
characterized by a unique PTPase signature motif-C (X)5 R containing the cysteine 
and arginine residues known to be essential for catalytic activity. Within the PTP 
(catalytic) domain the cysteine residue functions as a nucleophile and is essential 
                                                                                                                                                                Introduction 
19 
 
for catalysis. PTPs fall into three classes: (a) receptor PTP (b) non-receptor (non-
trans membrane) PTP (c) dual specificity PTP (DUSPs) as seen in Fig 1.6 
Receptor PTPs are predominantly found in the plasma membrane, whereas non-
receptor PTPs is localized to a variety of intracellular compartments, including the 
cytosol, plasma membrane and endoplasmic reticulum (Andersen et al., 2001; 
Zhang, 1998). 
Alterations in the expression or activity of these PTPs have known to cause 
pathophysiological consequences leading to many human diseases including 
cancer, diabetes/obesity, and autoimmune disorders 
 
 
Fig 1.6 Schematic representation of PTP family members- The PTP family includes receptor PTPs 
(RPTPs), dual-specificity PTPs (DUSPs) and non-receptor/soluble PTPs (NR-PTPs). All the receptor tyrosine 
phosphatases contain the tyrosine phosphatase motifs often in tandem and are distinguished by differences in their 
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extracellular domains. The cytosolic/non-receptor tyrosine phosphatases are further divided by the presence of 
various homology domains such as SH2 or PEST. The PTP catalytic domain is highly conserved and contains a 
single cysteine that is used in a cysteinyl-phosphate enzyme intermediate during dephosphorylation.DEP1 (high 
cell-density enhanced PTP-1); JSP1 (Jun amino-terminal kinase (JNK) stimulatory phosphatase); LAR (leukocyte 
common antigen related); PTP-PEST (PTP-proline, glutamate, serine and threonine-rich domain); SAP1 (stomach 
cancer-associated PTP); SHP (SH2-domain-containing PTP); PTEN (phosphatase and tensin homologue). Adapted 
from(Andersen et al., 2001).  
Genetic studies on human autoimmune disorders have shown strong association of 
LYP (Lymphoid tyrosine phosphatase –soluble phosphatase) with a broad 
spectrum of autoimmune diseases. LYP and its murine orthologs PEP (PEST-
domain enriched tyrosine phosphatase) is exclusively expressed in immune cells 
(Cohen et al., 1999). LYP/PEP functions as a negative regulator in T-cells, a 
missense C1858T single nucleotide polymorphism in the gene (PTPN22) encoding 
LYP results in gain-of-function rendering increased inhibition of T-cell signaling 
leading to autoimmune disorder (Vang et al., 2005). Hence much of the attention 
has been focused on the function of LYP/PEP and the pathway(s) it regulates 
which would help in providing new approach to treat autoimmunity.  
PEST–domain enriched tyrosine phosphatase- (PEP) 
This PTP is characterized by a so-called PEST (proline-glutamic acid-serine-
threonine) sequence. The human ortholog lymphoid tyrosine phosphatase (LYP-
encoded by PTPN22 gene) and mouse orthologs PEST-domain enriched tyrosine 
phosphatase (PEP- encoded by PTPN8 gene) share 89% homology between their 
PTP domains and 61% identity in their non-catalytic portion. LYP/PEP is 
characterized by 300 amino acid N-Terminal (PTP domain), and C-terminal 
domain that includes 4 putative poly-proline motifs (P1-P4) (Fig 1.7) (Cote et al., 
2002).  
 





Fig 1.7 Structure of PEP/LYP- PEP/LYP is characterized by an N-terminal phosphatase domain made of 
300 amino acid residues and C-terminal domain with 200 amino acid residues, which include four putative poly-
proline motifs (P1-P4) which are sites of interaction with SH3 domain containing proteins. 
In murine T cells, PEP is a potent negative regulator of T-cell receptor signaling, 
which acts by suppressing the activity of Src-like family of receptor tyrosine 
kinases, PEP knockout mice show positive selection in their thymi resulting in 
clonal expansion of memory and effector T cell pools (Hasegawa et al., 
2004).Substrate-trapping experiments in these cells have identified interaction of 
PEP with Csk (C-terminal Src kinase) which is mediated by the proline-rich motif 
(P1) in PEP with the SH3 (Src-homology3) domain of Csk (Cloutier and Veillette, 
1996). This complex between PEP and Csk has been shown to exert a synergistic 
inhibition on TCR signaling by acting on the PTKs like Lck and ZAP-70 (Cloutier 
and Veillette, 1999). 
PEP/LYP is a leading example of a genetic variant that confers risk of developing 
diverse autoimmune diseases, including type-1 diabetes, rheumatoid arthritis, 
autoimmune thyroid disease and systemic lupus (Hermiston et al., 2009). A single-
nucleotide polymorphism that changes arginine 620 to tryptophan (R620W) in this 
gene product is a common risk factor for Graves’ disease, rheumatoid arthritis and 
systemic lupus erythematous. In T cells the autoimmune-associated LYP-R620W 
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polymorphism interferes with the formation of the complex between LYP and Csk 
as a result this is a gain-of-function mutation in which there is more efficient 
negative regulation of TCR signaling (Fiorillo et al., 2010; Vang et al., 2005; Vang 
et al., 2012; Veillette et al., 2009).  
Association of PTPN22 with autoimmunity has potentially important therapeutic 
implications, since it has been proposed that inhibition of LYP/PEP activity, which 
would presumably enhance TCR signaling, could help prevent or treat such 
diseases(Yu et al., 2007)  
PEP has recently been shown, to be expressed in mast cells (Maier et al., 2007) 
however its function in these cells is still unknown.  As mast cell activation is 
known to have implications in autoimmune disorders, presence of this phosphatase 


















Mast cell activation involves IgE mediated FcεRI crosslinking leading to 
phosphorylation of many PTKs (protein tyrosine kinases) which then initiates 
downstream signaling cascade culminating in the release of inflammatory 
mediators. The activity of these PTKs are regulated by the PTPs (protein tyrosine 
phosphatases), any dysregulation in the function of these PTPs have known to 
cause autoimmune disorders. The leading example is the LYP/PEP which has 
strong linkage to autoimmunity. In T-cells, PEP functions as a negative regulator 
of signaling. PEP has recently been shown, to be expressed in mast cells (Maier et 
al., 2007)  and studies on PEP deletion showed no effect on mast cell numbers 
(Obiri et al., 2011, 2012) but PEP-/- mice are less susceptible to passive systemic 
anaphylaxis (Obiri et al., 2011, 2012) 
The aim of this study is to identify the molecular mechanisms for the observed 
differences in the antigen mediated anaphylaxis between the wild-type and PEP 
knock-out mice .Study the major IgE-FcεRI receptor signaling pathway that lead to 
mast cell degranulation and eventually causing anaphylaxis in mice.
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Acrylamide/Bis-Acrylamide Carl Roth Gmbh & Co., Karlsruhe 
Agarose Peqlab ., Erlangen 
Ammonium persulfate (APS) Carl Roth Gmbh & Co., Karlsruhe 
Ammonium Chloride Carl Roth Gmbh & Co., Karlsruhe 
β-Mercaptoethanol                                                                                                Carl Roth Gmbh & Co., Karlsruhe 
Bromophenol                                                                                                       Carl Roth Gmbh & Co., Karlsruhe 
Bovine Serum Albumin                                                                                    Sigma-Aldrich Chemical., Taufkirchen 
Chloroform                                                                                                        Merck KGaA., Darmstadt 
Dimethyl sulfoxide (DMSO)                                                                              Carl Roth Gmbh & Co., Karlsruhe 
Dithiothreitol (DTT)                                                                                                      Carl Roth Gmbh & Co., Karlsruhe 
ECL-Western Blotting Solution GE HealthCare., Freiburg 
Enolase-rabbit muscle                                                                                                 Sigma-Aldrich Chemical., Taufkirchen 
Ethanol                                                                                                                                    Carl Roth Gmbh & Co., Karlsruhe 
Ethidium bromide Sigma-Aldrich Chemical., Taufkirchen 
Formaldehyde                                                                                                              Merck KGaA., Darmstadt 
Glycerol                                                                                                                   Merck KGaA., Darmstadt 
Glycine                                                                                                                      Carl Roth Gmbh & Co., Karlsruhe 
Glucose                                                                                                                       Carl Roth Gmbh & Co., Karlsruhe 
Glycogen Peqlab ., Erlangen 
HEPES                                                                                                                         Carl Roth Gmbh & Co., Karlsruhe 
Isopropanol                                                                                                                  Merck KGaA., Darmstadt 
Magnesium chloride                                                                                                     Carl Roth Gmbh & Co., Karlsruhe 
Magnesium sulphate                                                                                                   Carl Roth Gmbh & Co., Karlsruhe 
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Methanol                                                                                                                     Carl Roth Gmbh & Co., Karlsruhe 
N,N,N’,N’,-Tetremethylethylendiamine(TEMED)                                                                Sigma-Aldrich Chemical., Taufkirchen 
PeqGOLD                                                                                                                   Peqlab ., Erlangen 
Sodium acetate Merck KGaA., Darmstadt 
Sodium chloride                                                                                                           Carl Roth Gmbh & Co., Karlsruhe 
Sodium dodecylsulfate                                                                                                  Carl Roth Gmbh & Co., Karlsruhe 
Sodium hydroxide                                                                                                        Carl Roth Gmbh & Co., Karlsruhe 
Tris-base                                                                                                              Carl Roth Gmbh & Co., Karlsruhe 
Tris hydrochloride                                                                                               Carl Roth Gmbh & Co., Karlsruhe 
Triton-X-100 Bio-Rad., Munich 
Trypan blue                                                                                                        Sigma-Aldrich Chemical., Taufkirchen 
Tween-20                                                                                                            Carl Roth Gmbh & Co., Karlsruhe 
 
2.1.2 Cell culture chemicals and cytokines 
Chemicals Source 
Dinitrophenyl-Human Serum Albumin(DNP-HSA)  Sigma-Aldrich Chemical.,Taufkirchen 
Foetal Bovine Serum(FBS), South American origin  Biowhittakker.,Belgium 
L-Glutamine  Gibco., Karlsruhe 
Iscove’s Modified Dulbecco’s Medium (IMDM)  Gibco., Karlsruhe 
Murine anti-DNP IgE (Clone SPE-7)                                                                                        Sigma-Aldrich Chemical.,Taufkirchen                                                                     
Murine Interleukin-3 (IL-3) recombinant                                                                     Biomol Gmbh., Germany 
Murine SCF-recombinant                                                                                                                                                                                                      kind gift from Dr.Michael Stassen  
(Stassen et al ,2006 )                                                                                                                                
Phosphate Buffered Saline(PBS)                         Gibco., Karlsruhe 










Primary  Antibody  
anti-β Actin SantaCruz., Heidelberg 
anti-AKT        Cell Signalling ., Frankfurt 
anti-Cbp /PAG  SantaCruz., Heidelberg 
anti-Csk Millipore., Schwalbach 
anti-Fyn SantaCruz., Heidelberg 
anti-Gsk-3β  Cell Signalling ., Frankfurt 
anti-JNK  Cell Signalling ., Frankfurt 
anti-LAT  SantaCruz., Heidelberg 
anti-Lyn  Cell Signalling ., Frankfurt 
anti-NFATc1 SantaCruz., Heidelberg 
anti-PTPN22 (PEP)  SantaCruz., Heidelberg 
anti-PlSrc  SantaCruz., Heidelberg 
anti-αTubulin  SantaCruz., Heidelberg 
Primary phosphospecific Antibody 
anti-phospho Btk SantaCruz., Heidelberg 
anti-phospho Gsk-3β        Cell Signalling., Frankfurt 
anti-phospho JNK Cell Signalling., Frankfurt 
anti-phospho LAT(Y-132) Abcam., London 
anti-phospho LAT(Y-191) Cell Signalling., Frankfurt 
anti-phospho Lyn (Y-505) Cell Signalling., Frankfurt 
anti-phospho Lyn (Y-527) Cell Signalling., Frankfurt 
anti-phospho Vav SantaCruz., Heidelberg 
anti-phospho PLCγ-1 Cell Signalling., Frankfurt 
anti-phosphotyrosine (Clone-4G10) Millipore., Schwalbach 
Secondary Antibody  
anti-Goat-HRP DAKO Diagnostika Gmbh., Hamburg 
anti-Rabbit-HRP      DAKO Diagnostika Gmbh., Hamburg 
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anti-Mouse-HRP DAKO Diagnostika Gmbh., Hamburg 
 
2.1.4 Oligonucleotides 
Primers for genotyping knockout mice  
KH-1 5’-AATGCCCGCTTGATGAGCAGAGGTCTG-3’ 
KH-2 5’-GGCTTCTTTCAGTAGTTGCTGCAGAAT-3’ 
KH-4  neo-Cassette 5’-TGCTAAAGCGCATGCTCCAGACTGC-3’ 
Primers for Real-Time PCR analysis  
36B4(Arbp) For  5’-GGACCCGAGAAGACCTCCTT-3’ 
Rev 5’-GCACATCACTCAGAATTTCAATGG-3’ 
IL-1β For  5’-AAGGAGAACCAAGCAACGACAAAA-3’ 
Rev 5’-TGGGGAACTCTGCAGACTCAAACT-3’ 
IL-2  For  5’-GAGACTTGTGCTCCTTGTCA-3’ 
Rev 5’-TCAATTCTGTGGCCTGCTTG-3’ 
 IL-4 For  5’-TCGGCATTTTGAACGAGGTC-3’ 
Rev 5’-GAAAAGCCCGAAAGAGTCTC-3’ 
 IL-6                                                                  For  5’-GAAATGATGGATGCTTCCAAACTG-3’ 
Rev 5’-GGATATATTTTCTGACCACAGTGATGAGG-
3’ 
 IL-10                                                                                                                                                                                               For  5’-CTTGCACTACCAAAGCCACA-3’
Rev 5’-AAGTGTGGCCAGCCTTAGAA-3’ 
IL-13                         For  5’-CCTGGCTCTTGCTTGCCTT-3’ 
Rev 5’-GGTCTTGTGTGATGTTGCTCA-3’ 
CCL-2 (MCP-1)                                                                                                          For 5’-ATCCCAATGAGTAGGCTGGAGAGC-3’ 
Rev 5’-CAGAAGTGCTTGAGGTGGTTGTG-3’ 
CCL-12  For  5’-CCTGTGGCCTTG GGCCTCAA-3’ 
Rev 5’-GAGGTGCTGATGTACCAGTTGG-3’ 
MIP-1α For  5’-ACCTGCTCAACATCATGAAGG-3’ 
Rev 5’-AGATGGAGCTATGCAGGTGG-3’ 
TNF-α For  5’-TACACTTCGGGGTGATCGGTCC-3’ 
Rev 5’-CAGCCTTGTCCCTTGAAGAGAACC-3’ 
NFATc1                                                                         For  5’-CAAAGGAGAGGTCGGACTCG-3’ 
Rev 5’-ACTGTAGTGTTCTTCCTCGGC-3’    
                                           
 PLSCR1                                                                                                                                                                                                   For  5’-GGATCCATGGACAAACAAAA-3’ 
Rev 5’- AAGCTTTTTCATTTTAACATC-3’ 
                                                                                                                                       Materials and Methods 
28 
 
 PPP3cb                    For  5’-TCTGTTCTCAGGGAGGAGAGT-3’ 
Rev 5’-CCAGCCAACACTCCACTAGG-3’ 
 Orai-1                                                                                                          For  5’-CCTGGCGCAAGCTCTACTTA-3’ 
Rev 5’-CATCGCTACCATGGCGAAGC-3’ 
 IP3R For  5’-TGCCTCCACAATTCTACGACTGA-3’ 
Rev 5’-TCCCACAGTTGCCCACAAAG-3’ 
STIM1 For  5’-TTGGGCCTCCTCTCTTGACT-3’ 
Rev 5’-TCCTGCTTGGCAAGGTTGAT-3’ 
 
2.1.5 Plasmid construct 
Plasmid Description 
pUbi-Renilla Luc Ubi-Renilla-luciferase construct was generated by 
replacing the growth hormone cDNA in pUbiGH (Schorpp 
et al. 1996) by Renilla reniformis luciferase cDNA 
(Promega., Mannheim ) 
p3xNFAT Luc Generously provided by Laurie Glimcher, Boston. USA. 
p6xNF-kB-tk-Luciferase (3Enh-tk-Luc) Construct described in (Israel et al., 1992) 
pIL-6-Luciferase (–158/111 IL-6- Luc) Construct described in (Stein and Yang, 1995) 
 p5xTRE-TATA-Luc (AP-1-Luc) Construct described in (Jonat et al., 1990) 
 p3×HA SR α JNK1, p3×HA SR α JNK1-APF, 
p3×HA SR   α JNK2, p3×HA SR α JNK2-APF. 
Constructs kindly provided by Dr. Michael Karin, 
University of California, San Diego, USA (Kallunki et al., 
1994). 
2.1.6 Inhibitors and other reagents 
Inhibitor Source 
C28- Bis (2-cyanoethyl) phenyl phosphine-Au(I)-Cl Generously provided by Dr. Amy Barrios, Utah, USA. 
L75N04- Benzofuran salicylate moiety Generously provided by Dr. Zhong-Yin Zhang, Indiana, 
USA. 
Reagents Source 
Taq Polymerase and Reverse transcriptase Promega., Mannheim 
Protein  and DNA ladder and dNTPs Peqlab., Erlangen 
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2.1.7 Mouse strain 
PEP knockout mice in which PEP was inactivated by homologous recombination 
was generated in the Lab of Andrew Chan (Hasegawa et al., 2004) and supplied by 
Genetech Inc., San Francisco. Briefly, PEP+/- embryonic stem cells were 
generated by homologous recombination, and then injected into C57BL/6 
blastocytes to yield chimeric mice that were crossed with pure C57BL/6 strain 
mice to generate PEP+/- germline mice. Successive crossing of mice yielding the 
PEP knock-out mice referred as PEP-/- in this thesis were done at ITG Animal 
Facility. All mice were in the animal laboratory of the ITG (Security Level S1, 
GenTG) under SPF (specific pathogen free) conditions. The rearing, growing and 
killing the mice and the animal studies were in compliance with the Animal 
Welfare Act. 
2.2 Methods 
2.2.1 Nucleic Acid Methods 
2.2.1.1 Genotyping of PEP knock-out mice 
Isolation of Genomic DNA  
For determining the genotype of the progeny of the PEP-knock-out mouse line-tail 
biopsies from newborn or adult mice were incubated in 200μl of lysis buffer 
(100mM Tris pH 8.5, 5mM EDTA, 0.2% SDS, 200mM NaCl, proteinase K 
100ug/ml) at 55°C for 2hour. The lysates were subsequently centrifuged for 5 min 
at 14,000 rpm (Eppendorf centrifuge 5417R) and the supernatant containing the 
genomic DNA was transferred into fresh 1.5ml eppendorf tube containing 200μl 
cold isopropanol for DNA precipitation. The DNA was centrifuged for 5 min at 
14,000 rpm and dried in a heating block at 37°C and then resuspended in 100μl TE 
buffer (10mM Tris pH 7.5, 0.1mM EDTA pH 8.0) by and then stored at -20°C.  
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Genotyping by PCR with specific gene locus primers 
Genomic DNA isolated from tail biopsies were used as a template in the PCR 
reaction, in which sequence specific oligonucleotides (Primers see 2.1.4) were 
used. The oligonucleotides KH1 (forward) and KH2 (reverse) were used, so that 
they anneal within the genomic sequence of PTPN22 gene, outside the left and 
right border, respectively, of the neo-cassette that was originally inserted in the 
exon-1 of the PTPN22 gene to disrupt it (Hasegawa et al., 2004). KH4 primer 
instead anneals within the neo-cassette sequence. The PCR reaction was carried 
out in a reaction volume of 20μl in the thermal cycler machine (GeneAmp
TM 
PCR 
System 2700, Applied Biosystem). The composition of the PCR master mix and 
the steps of the PCR programme are listed below.  
Composition of PCR Master Mix 
Reagents per Reaction 
DNA Template 4μl  
5x Go Taq Reaction Buffer 4μl 
dNTPs (10Mm) 0.5μl 
Forward Primer-KH1 (10pmol) 1μl 
Reverse Primer- KH2/KH4 (10pmol)                                                                                      1μl













Steps Temperature[°C]               Time 
Pre-heating 95                                                        3 min 
Denaturing DNA 95                                                        1 min 
Annealing- hybridization 
with primer 
55                                                        1 min 
Elongation 72                                                        1min 
Amplification Steps 2-4 repeated  through 27 cycles                                                                   
Hold                                                                   4                                                             - 
 
Two separate PCR reactions were set for each template DNA. The amplification 
products were subsequently separated on a 2% TAE Agarose gel. In the first PCR 
reaction, KH1 (forward) and KH2 (reverse) primer were used, wherein the 
amplified product of size 350bp would be obtained only if the template DNA 
contained a wild-type allele. In the second PCR reaction, KH1 (forward) and KH4 
(reverse) primer were used; in this case the product of size about 450 bp would be 
obtained only if the template DNA contained a mutated allele. 
DNA separation by Agarose-gel-Electrophoresis 
Separation of DNA fragments was done on a 2% w/v Agarose gel. For this 
purpose, 2% Agarose was dissolved in 1x TAE buffer (40mM Tris pH 7.2, 2mM 
sodium acetate, 1mM EDTA pH8) by heating. After cooling of the Agarose 
solution to about 60°C, Ethidium bromide to a final concentration of 0.3μg/ml was 
added and the Agarose was poured into a horizontal electrophoresis chamber. The 
polymerized gel was overlaid with 1x TAE buffer, and samples were loaded into 
the wells. The separation was carried out at 100 V. Using a trans-illuminator (IL-
350, Bachofer, Reutlingen), the DNA bands under UV light (256 nm) were 
visualized and photographed using Eagle Eye 
TM 
photo camera system. 
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2.2.1.2 RNA Analysis 
Isolation of total RNA from BMMC 
2-3 x 10
6 
/ml suspension of BMMC were transferred into 1.5 ml eppendorf tube 
and centrifuged (Eppendorf centrifuge 5415D) for 5 min at 2000 rpm after which 
the supernatant was removed. To lyse the cells, 1 ml of PeqGOLD RNAPure 
isolation reagent was added to the cell pellet and after 5 min of incubation at RT, 
RNA was extracted by adding 200μl of chloroform and vortexed for 15 sec 
followed by incubation on ice for 5 min and then centrifuged at 14,000 rpm for 10 
min at 4°C. 400 μl of the upper phase was taken into a fresh eppendorf tube and 
400μl of chloroform was added and vortexed followed by incubation on ice for 10 
min and further centrifuged at 14,000 rpm for 10 min at 4°C. To precipitate the 
RNA, 400μ of the upper phase was taken into fresh eppendorf tube containing 5μl 
glycogen, mixed and incubated for 5 min at RT. 400μl of isopropanol was added, 
mixed and incubated for 15 min on ice and then centrifuged at 14,000 rpm for 15 
min at 4°C. Supernatant was discarded and the RNA pellet was washed by adding 
1 ml of 75% ethanol, then vortex and centrifuged at 14,000 rpm at 4°C, this step 
was repeated twice. The pellet was dried by keeping at RT for 5 min. To elute the 
RNA, 20μl sterile RNAse-free water was added to the pellet and vortexed and 
incubated at 37°C for 10 min and then in heating block at 56°C for 3min. 1μl of the 
RNA extract was used to measure the RNA concentration. The RNA was then 
frozen in liquid N2 and stored at -80°C. 
Quantification of RNA 
To quantify the amount of RNA, the optical density (OD) at 260, 280 and 230 nm 
was measured with NanoDrop
TM 
and the software ND-1000(version 3.1.2). An 
OD260=1 corresponds to 40μg/ml RNA. A ratio of OD260 /OD280 ranging from 1.8-
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2.0 indicates a nucleic acid preparation relatively free from protein 
contamination.AratioOD260 /OD230 above 1.6 indicates a preparation free of organic 
chemicals and solvents. 
cDNA-synthesis and RT-PCR 
To create first strand of cDNA, 1ug of total RNA was transcribed into cDNA by 
means of Reverse Transcriptase M-MLV1 (Moloney Murine Leukemia Virus-
Reverse Transcriptase Promega., Mannheim). The cDNA preparation involves two 
steps, in the first step RNA first is incubated with 100pmol random hexameric 
primer for 5 min at 70°C, and then cooled on ice. In the second step Reverse 
transcriptase mix is added and the whole mixture was incubated in the thermo 
cycler machine. The composition of reverse transcriptase mix and the PCR 
programme used are listed below. 
Composition of Reverse Transcriptase- Mix 
Reagents Per Reaction (1μg RNA) 
5x M-MLV1-RT buffer 4μl 
dNTP (10mM) 2μl. 
M-MLV1-RT (200U/μl) 1μl 
 
PCR programme for cDNA synthesis 
Steps Temperature[°C]     Time 
1 25                                           10 min 
2 42.                                          60 min 
3 70                                           10 min 
 
After completion of the cDNA synthesis, the cDNA was diluted with DEPC water 
at 1:10 and stored at -20°C.A quality control PCR was run with GAPDH primers 
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using the cDNA as a template and the amplification product was separated by 
Agarose gel electrophoresis. 
Quantitative Real-Time PCR (qRT-PCR) 
For the analysis of cDNA, qRT-PCR e was performed using the device ABI 
StepOnePlus RT-PCR System (Applied Bio systems, Darmstadt, Germany).  In an 
ABgene® PCR plate 5μl cDNA template was added with 18μl of SYBR Master 
Mix (6μl sterile water, 1μl  of gene-specific primer pairs (each 10 pmol) and 10μl 
SYBR ® Green Mix buffer, Qiagen) end volume 20μl.The steps of PCR 
programme are listed below.  
PCR Programme 
Steps Temperature[°C]     Time 
Incubation 50                                           2 min 
Denaturation 95                                          15 min 
Denaturation 95                                          15  sec 
Annealing and Elongation 60                                          30 sec 
Amplification Steps 3-4 repeated  
Denaturation 95                                          15 sec 
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2.2.2 Protein Analysis 
2.2.2.1 Preparation of Total cell Lysates 
For the extraction of whole cell lysates for the immunoblot analysis NP40 lysis 
buffer was used. Approximately 2-5×10
6
 BMMC was harvested and then 
transferred into an Eppendorf tube and centrifuged for 5 min at room temperature 
at 2000 rpm. The medium was discarded and the cells were washed once with 1 ml 
PBS and centrifuged again. The cell pellet was resuspended in 55μl NP40 lysis and 
incubated for 20 min on ice. Thereafter, equal volume of 2x SDS sample buffer 
was mixed (Vortex) and immediately incubated for at least 5 min at 95 ° C in 
heating block. The lysate was briefly centrifuged at 12000 rpm, and then sonified 
with 6-8 pulses Ultrasonic disintegrator (level 2-3; Branson Sonifier, G. 
Heinemann, Schwäbisch Gmünd). 
Nonidet P-40  (NP-40) Lysis Buffer   
Nonidet P-40 0.1% 




Protease Inhibitor Cocktail  1% 
2X SDS-Sample Buffer   
SDS 4% 
Tris-HCl pH 6.8 160mM 
Glycerol 20% 
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2.2.2.2 Separation of Proteins by SDS-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
For the analysis of proteins by SDS-PAGE 12% separating gel was used. The 
Penguin Doppelgel System P9DS apparatus (Peqlab, Erlangen, Germany) was used 
to cast the polyacrylamide gel. About 20 ml of the resolving gel was poured and 
overlaid with 70% Rotisol. After polymerization the Rotisol was washed off with 
distill water and the separating gel was covered with 10 ml stacking gel and the 
comb of the appropriate number of wells were inserted before polymerization. The 
gel was then fixed in the running chamber and 1X Lammeli buffer was used for 
run. Around 10-40μl of the sample was loaded per well alongside with protein 
marker. Gel electrophoresis was carried out initially at 90V in the stacking gel and 
120-140V in the separating gel.  
SDS-PAGE 12 % Resolving          5 % Stacking  
Gel                                 Gel 
Acrylamide 12%                                5% 
Tris-HCl pH 8.8 375mM                          --------- 
Tris-HCl pH 6.8 ----------                          125 
SDS 0.1%                               0.1% 
APS 0.1%                               0.1% 






Glycine 200mM                        
SDS 0.1%                         
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2.2.2.3 Western Blot Analysis 
Proteins in SDS-polyacrylamide gels were subjected by electro-transfer using a 
Wet transfer chamber (Trans-Blot, Bio-Rad laboratories GmbH, Munich) onto a 
PVDF (polyvinylidene fluoride) membrane (Immobilon, Millipore) presoaked in 
methanol at 300-350 mA or 35V for minimum 8 h at 4°C in 1X Western Transfer 
Buffer.  
1X Transfer Buffer  
Tris 25mM 
Glycine 200mM                        
Methanol 10% (v/v)                      
 
Immunoblotting was performed according to individual instructions for each 
antibody. In order to reduce unspecific binding of the antibodies to the membrane, 
the blot was incubated in blocking solution 1X TBST supplemented with either 3-
5% (w/v) non-fat dried milk or  5% BSA according to the different antibodies that 
were going to be used, at RT  for 1 h with shaking.  
 
1X TBST  
Tris-HCl pH7.4 10mM 
NaCl 150mM                        
Tween 0.05%                
 
For detection of proteins of interest the membrane was incubated in blocking 
solution containing the appropriate primary antibody (optimal working dilution 
was determined empirically) at 4°C overnight under constant rotation. After 3 
washes of 10 min each in TBST buffer, the membrane was incubated for 1 hour in 
                                                                                                                                       Materials and Methods 
38 
 
the blocking solution containing a (1:2000) dilution of HRP (Horseradish 
peroxidase) conjugated secondary antibody. Once the membrane has been washed 
3 times 10 min each, detection of specific protein was achieved by enhanced 
chemiluminescence. This light-releasing reaction is based on the oxidation of a 
substrate, which is catalyzed by the horseradish peroxidase. For this purpose, the 
membrane was incubated for 1 min with ECL Western blotting reagent 
(Amersham, Braunschweig) as directed by manufacture. The signal was developed 
using X-ray film (Hyper film ECL, or MP, Amersham, Braunschweig). 
Western blots were scanned from film with an Epson Expression 1600 digital 
scanner (Epson, Long Beach, CA), and density was determined using Image J 
Software; intensities of multiple samples on a single blot were normalized to a 
single sample in each blot. 
2.2.2.4 Stripping of Western blot membranes 
To allow more than single use of Western blot membranes, the membranes were 
incubated in pre-warmed "stripping" solution for 30 min at 55-60°C with shaking.  
For the removal of β-Mercaptoethanol and SDS the membrane was washed 3 times 
in the 1xPBS for 15 min each. 
Stripping Solution  
Tris-HCl pH 6.8 62.5mM 
SDS 2%                        











BMMC are activated with IgE (1ug/ml) for 2 h 
and then stimulated with DNP-HSA (200ng/ml) for 30 min. The cells were then 
harvested, centrifuged for 5 min at 4°C at 1500 rev/min and washed twice with ice-
cold PBS + 1mM PMSF + 1% PIC. Subsequently, the cells were suspended in 0.5 
ml lysis Buffer (0.1% Nonidet P-40, 200mM boric acid, 160mM NaCl, 5mM 
EDTA, and 1mM PMSF, 1mM sodium-orthovanadate, 1% PIC) and kept on ice for 
20 min. The lysates were centrifuged for 20 min at 4°C 12,000 rpm / min and the 
supernatant was transferred to a new eppendorf tube. In parallel, 50μl of 50% 
protein G-Sepharose beads were incubated with 5μg of protein-specific antibodies 
or with 5ug IgG control antibody for 2 h at 4°C. After incubation, the beads were 
centrifuged and the unbound antibody is removed and 100μl of cell lysate is added 
on to the beads and the control input is stored at -20°C. The beads alongwith the 
lysate is incubated overnight at 4°C (rotating); the beads are then centrifuged for 
1min at 1400 rpm at 4°C. Supernatant is carefully removed and the beads are 
washed 5 times with ice-cold 1 ml lysis buffer. The bound protein is eluted by 
adding 2% SDS sample buffer and incubating at 95°C for 10 min alongwith the 
input control. The amount of protein immunoprecipitated was analyzed by 
performing immunoblot as described in Western Blot Analysis.                         . 
The amount of tyrosine phosphorylated proteins was corrected for the amount of 
proteins immunoprecipitated as determined by densitometry of immunoblots after 
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2.2.2.6 In-Vitro Kinase Assay 
Lyn was immunoprecipitated by incubating lysates from 8-10×10
6 
BMMC 
(stimulated and non-stimulated) with 5μg anti-Lyn mouse antibody as described in 
Co-immunoprecipitation. Immunoprecipitates were then washed twice with lysis 
buffer without detergent and then once with kinase assay buffer (20mM Tris, pH 
7.6, 10mM MgCl2, and 1mM Na3VO4). After washing, Lyn immunoprecipitates 
were subjected to in vitro kinase assays by adding 200μl of kinase assay buffer 
containing 1mM ATP and 30μl of prepared substrate Enolase (acid-denatured) as 
an exogenous substrate. Samples were then incubated at 37 °C for 2 h. Reactions 
were quenched by the addition of 50μl of 5× non-reducing SDS sample buffer 
followed immediately by boiling and then subjected to immunoblot analysis. 
Substrate was prepared by incubating 50μl of 1mg/ml Enolase with 50μl of 50mM 
sodium acetate at 30°C for 10 min, followed by neutralization with 60μl 1 M Tris 
(pH 8.8) and 840μl of kinase buffer. Kinase activity was determined as the 
intensity of phosphorylated Enolase following an in vitro kinase assay divided by 
the amount of Lyn in the same lane 
2.2.3 Cell Culture Methods 
2.2.3.1 Cell Culture 
All cell culture work was done in a laboratory at a security level Safety cabinet 
(Class II, Thermo Electron, and Dreieich). BMMC were incubated at 37°C, 5-6% 
CO2 and 95% humidity in an incubator (Forma Scientific Labor Tec GmbH, 
Gottingen).  After harvesting the cells were washed either in Iscove’s Modified 
Dulbecco’s Medium (IMDM) or sterile magnesium and calcium-free PBS (137mM 
NaCl, 2.7mM KCl, 6.5mM Na2HPO4, and 1.5mM KH2PO4) was used. 
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2.2.3.2 Generation of bone marrow-derived mouse mast cells (BMMC) 
For the generation of bone marrow-derived mouse mast cells (BMMC) PEP mice 
(Section 2.1.7), aged 8-10s week killed by cervical dislocation. Tail biopsies were 
taken for genotyping (Section 2.2.1.1). The mice were disinfected by immersing in 
75% Rotisol. The skeletal muscle was removed from the bones of the posterior 
limbs and the intact femurs and tibias were isolated and kept in cold IMDM at 4°C. 
In cell culture laboratory bones were washed once with 75% Rotisol, and three 
times with PBS. After cutting the Epiphyses of the bone under sterile conditions, 
the bone marrow was repeatedly flushed through by means of cold IMDM using a 
10 ml syringe (0.45 x 25 mm needle) until the Medullary cavity was reasonably 
free from blood. The cell suspension was collected in a 50 ml falcon tube and was 
centrifuged for 10 min at 1300 rpm at RT and the supernatant was discarded. The 
cell pellet was resuspended in 5 ml IMDM and centrifuged again for 10 min at 
1300 rpm at RT. To lyse the erythrocytes, the cell pellet was resuspended for 2 min 
in 2 ml (for 3-5 mice) ACK lysis buffer at RT after which the reaction was 
terminated by addition of 8 ml of cold IMDM.  




KHCO3 1mM                        
EDTA  1mM                      
 
For the removal of bone fragments, the Cell suspension was applied on a 70μm 
nylon Falcon cell strainer (BD Bioscience) and centrifuged again. The cells were 
then resuspended in 1 ml of the culture medium. After determining the number of 
cells, the cells were seeded at a density of 2x10
6
 cells / ml of growth medium in 
24-well plates (Greiner) at 1 ml / well and cultured for 4 to 5 weeks. Thereby every 
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2-3 days, half of the medium was carefully removed, and the non-adherent cells 
with the help of a 1-ml Pipette were transferred after being washed several times in 
a new 24-well plate and fresh medium supplied. The adherent cells were discarded.  
BMMC Culture/Growth Medium 500 ml 
Iscove’s Modified Dulbecco’s Medium 
IMDM 
 






Stem Cell Factor (SCF) 100ng/ml 
 
2.2.3.3 Stimulation of BMMC 
For Phosphorylation and Co-Immunoprecipitation studies BMMC at a cell density 
of 2-5×10
6 
cells/ml were cultured in Growth medium, 2 h prior to harvesting the 
cells, anti-DNP IgE was added in a final concentration of 1μg / ml. Finally, the 
cells were transferred into a 1-ml Eppendorf tube, and centrifuged for 5 min at 
1500 rpm (Eppendorf bench centrifuge). The medium was discarded and the cells 
were washed once with 37 ° C warm PBS and again centrifuged and resuspended 
in 50μl of growth medium and 50μl of DNP HAS was added to a final 
concentration of 200ng/ml and incubated at 37 ° C heating block at indicated time 
points.  
For stimulation of BMMC by stem cell factor (SCF), the cells were initially 
cultured in IMDM growth medium and then starved by culturing in growth 
medium without IL-3 and SCF. Subsequently, the cells were stimulated with SCF 
at various concentrations ranging from 50-400 ng/ml and for indicated time points. 
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In some experiments, BMMC were incubated with PEP inhibitors L75N04 (5μM 
and 20μM) and C28 (5μM) for 1 h. All the inhibitors were dissolved in dimethyl 
sulfoxide (DMSO), aliquoted and stored at -20 ° C. 
Other Experimental Methods 





BMMC after stimulation were rested on ice for 1min, and then 
lysed in 1 ml of lysis buffer containing 10mM Tris-HCl (pH 8.0), 50mM NaCl, 
10mM EDTA, 1mM Na3VO4, 10mM glycerophosphate, 1mMPMSF and 1% (v/v) 
Brij-58. After 15 min, the lysate was homogenized by passing 10 times through a 
27-gauge needle and adjusted to 40% (w/v) sucrose by adding an equal amount of 
80% sucrose. A gradient was formed by successive addition of 0.2 ml of 80% 
sucrose stock to the bottom of a polyallomer tube (13 by 51 mm), followed by 0.5 
ml of 60% sucrose, 1.5 ml of 40% sucrose (containing the cell lysate), 0.8 ml of 
35% sucrose, and 0.5-ml aliquots of  30, 20, and 15% sucrose. Sucrose solutions 
were prepared by mixing the appropriate amount of the gradient buffer (25mM 
Tris-HCl [pH 7.5], 12mM NaCl, and 2mM EDTA) and 80% sucrose. Tubes were 
centrifuged at 210,000 g for 12 h at 4°C using a SW55Ti rotor (Beckman 
Instruments).After centrifugation, 10 fractions of 500μl were collected from top of 
the tube and then analyzed  by immunoblotting ; lipid rafts were found in the upper 
4 fractions 
2.2.5 Degranulation Assay 
5×10
6
 cells/ml BMMC were harvested washed and re-suspended in 100 μl of 
Tyrodes buffer (135mM NaCl, 5mM KCl, 1mM MgCl2, 1mM CaCl2, 5mM 
Glucose, 20mM HEPES, pH 7.4) at 37°C. Cells were then subjected to 
centrifugation at 2000 rpm at 4°C for 5min. The supernatant was aspirated and the 
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cell pellet was carefully resuspended in 200 μl Tyrodes Buffer + 0.5% TritonX-100 
and then incubated on ice for 15 min. For complete lysis the cells were then 
centrifuged for 5min at 13,000 rpm. 50 μl of each sample was transferred to a 96-
well plate (Falcon; BD Bioscience), and 50 μl of 1mM pNAG(p-nitrophenyl N-
acetyl-β-d-glucosaminidine) is added to each well and incubated for 90 min at 
37°C. Finally 150μl of Glycine (0.2M, pH10.7) is added and the color change is 
measured spectrophotometrically by measuring OD in an Ultra micro- plate reader 
ELx808IU (Bio-Tec-Instruments, Inc.) at a wavelength of 405 nm. Percent 
degranulation was calculated as follows (released activity/total activity) ×100. 
2.2.6 Adhesion Assay 
BMMC were cultured overnight in IL-3 and Kit-ligand (SCF-stem cell factor) free 
medium. Cells were washed with HEPES buffer + 0.04% bovine serum albumin 
(BSA) and 3-5×10
6 
BMMC were seeded per well in a 96-well tissue culture plate 
(Falcon; BD Bioscience) precoated with 5μg/ml fibronectin and blocked with 4% 
BSA. The cells were then either left unstimulated or stimulated with 50 and 100ng 
of SCF for 30 min. Non-adherent cells were removed by carefully washing the 
wells once. Wells used for total cells were not washed. Cells were lysed with 0.1 % 
TritonX-100, and 100μl of the Lysate was then transferred to a 96-well plate for β-
hexosaminidase determination as described in Degranulation assay. The percent 
adherent cells were calculated as [(absorbance of sample – background) / 
(absorbance of total cell lysates – background)] × 100%.   
2.2.7 Transient Transfection of BMMC 
The transfection of BMMC with plasmid DNA was carried out by Electroporation 
using the Nucleofector II (Amaxa), using the Program T-023. For this BMMC 
were first washed twice with IMDM 5 min and centrifuged at 1500 rpm. 
Approximately 4-6×10
6
 cells in 100 μl were resuspended in 37°C-warm IMDM 
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resuspended. Around 10μg of Plasmid DNA was filled in this suspension and it 
was filled by another 100μl IMDM. The 200μl cell suspension was transferred into 
the cuvette (Amaxa) and treated in the Nucleofector electroporation. Thereafter 
immediately 800μl of pre-warmed growth medium was added to the cuvette and 
the cells were pipetted out   into a 6-well plate filled with 2 ml of pre-warmed 
growth medium and incubated for 24 h and then stimulated accordingly. 
2.2.8 Luciferase Reporter Gene Analysis 
8×10
6
 BMMC cells were transfected with 4.3μg of reporter luciferase plasmid and 
0.8μg of pUbi-Renilla Luc vectors by electroporation using the Nucleofector II 
(Amaxa) Program T-023. The cells were then plated in 2 ml culture medium for 24 
h to recover from the electroporation. The cells were then left unsensitized or 
sensitized with anti-DNP IgE for 18 h. They were then left untreated or activated 
with DNP-HSA for 8 h. Thereafter they were lysed in passive lysis buffer 
(Promega Mannheim, Germany) and the lysates were centrifuged at 10,000 rpm for 
10 min at 40 C. Firefly and Renilla luciferase activity were then measured using a 
Perkin Elmer luminescence counter using 20μl lysate with 70μl reaction buffer 
(25mM Glycylglycine, 15mM MgSO4, 4mM EGTA, pH 7.8 with 1mM DTT and 
2mM ATP)  30μl D-(-)-luciferin solution (0.28 mg / ml 0.5 M Tris, pH 7.5) were 
mixed and were measured immediately. For determination of the Renilla luciferase 
activity were 20μl lysate with 100 coelenterazine μl buffer (0.2 M KH2PO4, 0.2 M 
K2HPO4, pH 7.6) and 0.2μM coelenterazine. The luciferin and coelenterazine 
oxidation released luminescence was measured (relative Light units, RUL), the 
Quotient from RUL [luciferin] / [coelenterazine] was formed. 
2.2.9 Cytosol/Nuclear extraction Assay 
Approximately 2-5×10
6
 BMMC was harvested and then transferred into an 
Eppendorf tube and centrifuged for 5 min at 4°C at 2000 rpm. The pellet was 
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washed twice with ice-cold PBS. The pellet was resuspended in BUFFER A 
(10mM Tris-HCl pH 8.0, 1mM EDTA, 100mM NaCl, 1% Protease inhibitor 
cocktail) and kept on ice for 5 min. 2μl of MgCl2 (2mM final concentration) is 
added to the suspension to keep nuclei intact and then add 10μl of 10% NP-40and 
vortex for 10 sec and then centrifuge for 3 min at 4000rpm at 4°C. Collect the 
supernatant which is the NP-40 soluble cytoplasmic fraction, the pellet is 
resuspended into BUFFER B (10mM Tris-HCl pH 8.0, 1mM EDTA, 1% Protease 
inhibitor cocktail) and then add salt to extract nuclei (1/10 volume of 2.5 M 
ammonium sulfate) mix thoroughly and incubate on ice for 45 min and then 
centrifuge for 30 min at 40,000 rpm at 4°C in Ultracentrifuge and collect the 
supernatant which contains the nuclear fraction. 
2.2.10 Preparation of RNA for Microarray 
Total RNA was prepared from 10 X 10
6
 cells from resting and activated WT and 
PEP-/- BMMC using TRIzol reagent (Invitrogen Life Technlogies) according to 
manufacturer’s instructions. Further purification of RNA was done using the 
RNeasy kit (Qiagen). This RNA sample was then sent to Dr. Ludger Klein-Hitpaß 
(University Essen) for micro-array analysis. In his Lab following procedures were 
followed. Approximately 200 ng of total RNA was converted to cDNA using the 
Superscript II RNA reverse transcriptase (Invitrogen Life Technologies). Double-
strand cDNA was produced with an oligo (DT) primer containing the T7 RNA 
polymerase site at the 5’end. The cDNA was labeled and biotinylated nucleotides 
with the Affymetrix labeling kit as per the manufacturer’s instructions. The cDNA 
was hybridized for 16 hr to the Affymteric mouse genome chip (430 A) containing 
14,000 genes. Chips were washed, stained with Streptavidin – PE and read using 
the GC Scanner 300 with G7 update according to the manufacturer’s instructions. 
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2.2.11 Passive Systemic Anaphylaxis 
8-9 month old female mice (20-25g) were sensitized by intra-peritoneal (i.p) 
injection of anti-DNP IgE (1mg/kg) for 24 h. C28 (5μM) or  L75-NO4 (20µM) or 
vehicle sterile Magnesium and Calcium –free  PBS ( 137Mm NaCl, 2.7mM KCl, 
6.5mM Na2HPO4, 1.5mM KH2PO4 ) were administered by IP injection 1 h to the 
end of sensitization period. Anaphylaxis is then initiated by intravenous (i.v) 
injection of 200μl dinitrophenyl human serum albumin DNP-HSA (1 mg/ml PBS). 
Body temperature was measured with a Micro-life VT 1831 Vet-Temp (Tier-shop, 
Trier, Germany) every 5 min over a period of 60 min. 
2.2.12 Statistics 
Data are represented as Mean values ± Standard Error of the Mean (n≥3, n is a 
positive integer). Group comparisons were done using the Mann-Whitney U-test. 
Where more than two groups were involved, the results were analyzed for 
differences using the One-Way Analysis of Variance (ANOVA) and the significant 
difference between groups were examined by the Newman-Keul’s range test at 5% 
level of significance. All graphs were plotted using the GraphPad Prism software 
version 5.0 (GraphPad, San Diego, CA).  




3.1 Interaction of PEP with Src-like kinases 
PEP is a cytosolic tyrosine phosphatase expressed primarily in hematopoietic 
tissues like thymus, fetal thymus, spleen and lymphoid tissue, including T and B 
cells as well as myeloid cell lines (Cohen et al., 1999). Overexpression studies in T 
cell lines have demonstrated a negative regulatory role for PEP/LYP in T cell 
receptor signaling and identified its substrate as the activating loop tyrosine of Lck 
(Cloutier and Veillette, 1999; Gjorloff-Wingren et al., 1999). Substrate trapping 
experiments in T-cells have shown components of TCR signal transduction 
machinery such as ZAP-70, CD3ζ, CD3ε, and Vav to be the additional  targets of 
LYP apart from Lck (Wu et al., 2006). PEP has recently been shown to be 
expressed in mast cells (Maier et al., 2007) and to positively regulate antigen-
mediated anaphylaxis (Obiri et al., 2011), but its mode of action is still not clear.  
In order to understand the mechanism of action of PEP in mast cell signaling, its 
interaction partners needs to be determined. Femurs were isolated from 8-10 week 
old PEP wild type (PEP+/+) and PEP knock-out (PEP-/-) mice and the bone 
marrow was flushed into the culture medium containing IL-3 and SCF. Bone 
marrow derived cells (BMMC) were cultured for 4-5 weeks in order to generate 
homogenous mast cell cultures. These cells were sensitized with antigen-specific 
immunoglobulin E (IgE anti-dinitrophenyl) for 2 hours and the cells were then 
stimulated with specific antigen, dinitrophenyl-human serum albumin (DNP-HSA) 
for 30 min. Cell lysates were prepared and then subjected to immunoprecipitation 
and then immunoblotted with specific antibodies. 
Co-immunoprecipitation studies revealed that PEP in BMMC interacts with src-
like kinases (Lyn, LAT and PLC-γ) either in the presence of IgE alone or IgE/DNP 
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but not in the absence of antigen (Fig 3.1A, compare lanes 5, 6 with 4). There was 
no interaction in PEP -/- BMMC (Fig 3.1A, lanes 13-15). Hence PEP interacts with 
kinases like Lyn, LAT, PLC-γ only in the presence of antigen. 
Unlike these kinases, another src-like kinase Csk, was constitutively associated 
with PEP in PEP+/+ BMMC even in the absence of IgE (Fig 3.1A, compare lanes 
5, 6 with 4) while no interaction was detected in PEP-/- BMMC (Fig 3.1A, lanes 
13-15).  
To confirm these findings, Lyn and Csk were immunoprecipitated and interaction 
of PEP with these kinases was analyzed in a Western blot in PEP+/+ and PEP-/- 
BMMC (Figs 3.1B and 3.1C). PEP was indeed found to be associated with Lyn 
only in the presence of antigen (Fig 3.1B, lanes 3-4) while PEP was again 
constitutively associated with Csk (Fig. 3.1C, lanes 3-4). In these studies no 
interaction was seen in the absence of PEP in PEP-/- BMMC (Figs 3.1B and 3.1C).  
In T cells, PEP and Csk interaction cooperatively inhibit TCR signaling by 
dephosphorylation of positive regulatory residue Tyr
394
 in Lck by PEP and 
phosphorylation of negative regulatory residue Tyr
505 
by Csk. In order to study the 
effects of PEP-Csk interaction on mast cell signaling, association of Lyn (like Lck 
in T-cells, Lyn initiates the IgE mediated signaling in mast cells) with Csk in 
PEP+/+ and PEP-/-BMMC was examined. Also to determine whether PEP 
interacts with Csk and Lyn independently or whether the three proteins can be in a 
complex, the interaction of Csk and Lyn was analysed. 




Fig 3.1 Association of PEP with src-like kinases - (A) 8-10 x 106 PEP+/+ and PEP-/- BMMC were 
treated with anti-DNP IgE (1µg/ml) for 2 h and activated with DNP-HSA (200 ng/ml) for 30 min. Cell lysates were 
immuno-precipitated using Protein A sepharose incubated with anti-PEP antibody or IgG control and subjected to 
immunoblot analysis with the indicated antibodies PEP, PLCγ1, Lyn, Csk and LAT. (B) and (C) PEP+/+ and PEP-/- 
BMMC were treated with anti-DNP IgE (1µg/ml) for 2 h and activated with DNP-HSA (200 ng/ml) for 30 min. Cell 
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lysates were immuno-precipitated with anti-Lyn (B) or with anti-Csk (C) and subjected to immunoblot analysis with 
anti-Lyn and anti-CSK antibodies. The results are representative of five independent experiments. 
Co-immunoprecipitation with Csk, showed that in PEP+/+ BMMC, Lyn was 
associated with Csk only in the presence of antigen (Fig 3.1.1A lanes 3-4). In 
contrast, in PEP-/- BMMC, Lyn was found in association with Csk in the absence 
of antigen and this interaction was further enhanced, following IgE crosslinking 
(Fig 3.1.1A, compare lanes 9 and 10). These observations suggest that in mast 
cells, under resting conditions, the association of PEP with Csk is unable to interact 
with Lyn. Unlike other Src family kinases, Csk is devoid of the amino-terminal 
myristylation signal for localization at the plasma membrane. Thus it is 
cytoplasmic and interacts with PEP at this cellular localization. To form a complex 
with Lyn, it needs to be recruited to the plasma membrane (Honda et al., 1997; 
Yasuda et al., 2002) 
 
 
Fig 3.1.1 Interaction of Csk with Lyn - (A) 8-10 x 106 PEP+/+ and PEP-/- BMMC were treated with anti-
DNP IgE (1µg/ml) for 2 h and activated with DNP-HSA (200 ng/ml) for 30 min. Cell lysates were immuno-
precipitated using Protein A sepharose incubated with anti-Csk antibody or IgG control and subjected to 
immunoblot analysis with anti-Lyn and anti-CSK antibodies. The results are representative of three independent 
experiments. 




3.2 PEP deficiency induces Csk recruitment to the lipid rafts 
The plasma membrane contains areas enriched in cholesterol and sphingolipids 
present in all eukaryotic cells that are referred to as lipid rafts (Draber and 
Draberova, 2002). Lipid rafts are important sites for protein tyrosine kinase-
mediated protein-protein interaction that are involved in the initiation of receptor 
signaling pathways. These membrane rafts are also involved in mast cells signaling 
and are enriched with signaling molecules involved in the FcεRI mediated pathway 
(Silveira et al., 2011). Tyrosine phosphorylation of the high affinity 
immunoglobulin IgE receptor (FcεRI) by the Src family kinase, Lyn is the first 
known biochemical step that occurs during activation of mast cells after cross-
linking of FcεRI by antigen. This coupling of Lyn and FcεRI is predominantly 
found in lipid rafts (Kovarova et al., 2001; Radeva and Sharom, 2004; Sheets et al., 
1999). 
To determine whether the complex of PEP and Csk is recruited to the lipid raft 
when mast cells are activated, cell lysates from PEP+/+ and PEP-/- BMMC before 
and after receptor activation were analyzed. The lysates were solubilized in 
detergent and then subjected to sucrose density gradient centrifugation that 
separates detergent resistant (rafts/nonsoluble) membrane from the light (soluble) 
fractions. These fractions were then subjected to western blot analysis and then 
immunoblotted with specific antibodies and the densitometric quantification of 
signal were carried out (Fig 3.2) 
Under resting conditions, in PEP+/+ BMMC, Csk and PEP are present in the 
soluble fractions (Fig 3.2A, lanes 5-10) while Lyn and Cbp/PAG (a trans-
membrane protein that is known to be present in lipid rafts (Ohtake et al., 2002b) 
                                                                                                                                                                           Results 
53 
 
are present in the raft fractions (Fig 3.2A, lanes 1-4). After IgE/DNP crosslinking, 
both Csk and PEP are recruited to the lipid rafts (Fig 3.2A, right panel, lanes 1-4). 
Quantification of the signals in the Western blot experiments show that while no 
detectable PEP and Csk were present in the lipid rafts at the resting stage, around 
20-40% of these proteins were found in the raft following IgE receptor 
crosslinking.  
In case of PEP-/- BMMC under unstimulated conditions around 20-30 % of Csk is 
already present in the raft fractions (Figs 3.2C, lanes 1-4 and 3.2D) and the rest in 
soluble fraction (Fig 3.2C, lanes 5-10). In presence of antigen, the proportion of 
Csk in the lipid raft is increased to more than 40 % (Figs 3.2C, right panel, lanes 1-
4 and 3.2D).  
These results show that while Lyn is always present in the lipid rafts, differences 
exist in the level of Csk protein in the lipid rafts of PEP+/+ and PEP-/- BMMCs. In 
PEP+/+ BMMC, Csk is recruited to the lipid rafts only after activation of the cells 
while in PEP-/- BMMC, Csk is already present in the lipid rafts but its level is 
increased upon antigen stimulation. This is in accordance with the 
immunoprecipitation results where Csk interacts with Lyn only in the presence of 
antigen stimulation in PEP+/+ BMMC whereas  there is interaction of Csk with 
Lyn under unstimulated conditions which further enhances after IgE/DNP 
crosslinking in the PEP-/- BMMC.   
 








Fig 3.2 Absence of PEP leads to increased recruitment of Csk into the Lipid Rafts - (A) and 
(C) Cell lysates (unstimulated and stimulated) from wt and PEP knockout BMMC were subjected to sucrose 
gradient centrifugation and lipid rafts fractions were isolated. The PEP, CSK and Lyn content of raft or non-rafts 
fractions isolated was visualized by immunoblotting with respective antibodies. An anti-Cbp/PAG antibody serves 
as a marker of Lipid rafts.  Fractions 1-4 represent detergent insoluble while 5-10 represent detergent soluble 
membrane. (B) and (D) The graph represents the densitometric quantification of amount of Csk and PEP present in 
rafts and soluble fractions from 5 independent experiments. (Mean±S.E.M, n=5) 
 
3.3 Impact of PEP deficiency on Cbp/PAG phosphorylation 
The ability of Csk to relocate from cytosol to plasma membrane and its 
involvement in inhibiting Src-PTKs (protein tyrosine kinases) is due to the 
presence of a plasma-membrane associated, Csk binding molecule, Cbp/PAG that 
mediates recruitment of Csk to Src-PTK. Cbp is exclusively localized in the GM1 
ganglioside (monosialotetrahexosylganglioside) -enriched detergent insoluble 
membrane (DIM) domain which is important in receptor mediated signaling 
(Takeuchi et al., 2000). When phosphorylated at Tyr
314
 Cbp/PAG associates with 
Csk and brings it into proximity with the membrane associated src like kinases 
(Ohtake et al., 2002b).  
As interaction of Csk with Cbp requires tyrosine phosphorylation of Cbp/PAG 
(Horejsi, 2004), hence Cbp/PAG immunoprecipitates from PEP+/+ and PEP-/- 
BMMC were probed with phosphotyrosine antibody to determine the 
phosphorylation status of Cbp/PAG. In the PEP+/+ BMMC, Cbp/PAG is non-
phosphorylated but phosphorylation begins 5 min after IgE crosslinking, reaching a 
peak at 15 min and decreasing slowly at 30 min (Fig 3.3A, lanes 1-6). In contrast, 
in PEP-/- BMMC, Cbp/PAG is constitutively phosphorylated and IgE crosslinking 
further increases its level of phosphorylation (Fig 3.3A, lanes 7-12). 
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In co-immunoprecipitation, Cbp/PAG immunoprecipitates from PEP+/+BMMC 
showed interaction with PEP and Csk only in presence of antigen (Fig 3.3B, 
compare lane 4 with 3), while in PEP-/- BMMC Csk interacts with Cbp/PAG even 
in the absence of antigen and this interaction is enhanced following IgE 




Fig 3.3 Absence of PEP leads to hyper-phosphorylation of Cbp/PAG - (A) 5-6 x 106 PEP+/+and 
PEP-/- BMMC were treated with anti-DNP IgE (1µg/ml) for 2 h and activated with DNP-HSA (200 ng/ml) for 
indicated time points. Cell lysates were immuno-precipitated with anti-Cbp/PAG antibody and subjected to 
immunoblot analysis with anti-phosphotyrosine antibody (top panel) and then the filter was stripped and reprobed 
with anti-Cbp/PAG antibody (bottom panel). (B) Cell lysates from PEP+/+ and PEP-/- BMMC were treated as 
described above and activated with DNP(200ng/ml) for 30 min and immunoprecipitated with anti-Cbp/PAG 
antibody  and then immunoblotted with anti-Cbp/PAG antibody, anti-PEP antibody and anti-Csk antibody 
respectively. The results are representative of three independent experiments. 
These results suggest that Cbp/PAG only in its phosphorylated state can be co-
immunoprecipitated with Csk as seen in PEP-/- BMMC but not in the non-
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3.4 Impact on Lyn activity of hyper-phosphorylation of Cbp/PAG and 
increased recruitment of Csk to lipid rafts in PEP-/-BMMC 
Cross-linking of IgE-FcεRI complexes on mast cells by multivalent antigen 
initiates a series of signaling events that culminate in the exocytosis of mediators 
of the allergic response. The earliest biochemical event following receptor 
aggregation is the activation of Lyn and subsequent phosphorylation of the ITAM 
sequences on FcεRI β and γ subunits (Kinet, 1999; Parravicini et al., 2002).  
Lyn like other Src family kinase is regulated by protein interactions through its 
SH2/SH3domain as well as via phosphorylation events. It possesses a negative-
regulatory phosphotyrosine Y-508 located near its carboxyl terminus. This 
phosphotyrosine is able to interact with Lyn’s N-terminal SH2 domain occluding 
the catalytic site of this kinase from accessing external substrates. Csk negatively 
regulates Lyn activity by phosphorylating the negative regulatory tyrosine residue 
at its COOH terminus. This event is facilitated by Cbp/PAG which not only 
relocates Csk to the membrane but also elevates the affinity of Csk for Lyn 
(Takeuchi et al., 2000). Activation of Lyn involves dephosphorylation of the C-
terminal tyrosine Y-508 to release the auto-inhibitory configuration of the kinase 
domain. Lyn can then trans-auto-phosphorylate Y-397 within its activation loop to 
generate a highly active enzyme (Xu et al., 1999). Hence the activation 
/inactivation regulatory cycle of Lyn is controlled by two proteins; Csk and 
Cbp/PAG.  
Since increased phosphorylation of Cbp/PAG and enhanced recruitment of Csk to 
the lipid rafts which was observed in the PEP-/- BMMC are implicated in the 
negative regulation of Lyn, the activity of this kinase was determined in PEP-/- 
BMMC and compared to the control PEP+/+ BMMC. An in-vitro kinase assay for 
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determining Lyn activity was performed, also the phosphorylation status of both 
the positive (Y-397) and negative (Y-508) regulatory sites were determined 
Lyn immunoprecipitates from PEP+/+ and PEP-/- BMMC were subjected to in-
vitro kinase assay wherein they were incubated with 1mM ATP and 30μl of  
1mg/ml of prepared substrate (acid-denatured enolase) for 2 h  at 37°C  and then 
subjected to immunoblot analysis  and then probed with anti-phosphotyrosine 
antibody to detect the phosphorylation of Enolase. Phosphorylation status of Lyn at 
sites Y-508 and Y-397 was determined by using  the same Lyn immunoprecipitates 
and probing them with specific phospho-Lyn antibodies. 
Activity of Lyn in PEP-/- BMMC was markedly reduced compared to PEP+/+ 
BMMC after receptor crosslinking, as judged by the PTK activity towards 
exogenous substrate enolase in the in-vitro kinase assay (Fig 3.4A, compare lanes 
7-12 to lanes 1-6). In addition, there was a reduced phosphorylation of Lyn at 
Tyr
397
 in PEP-/- BMMC compared to PEP+/+ BMMC following IgE crosslinking 
(Fig 3.4A compare lanes 7-12 with 1-6). Quantification of the kinase assay and the 
Tyr
397
 activity also represents the significant reduction seen in PEP-/- BMMC (Fig 
3.4 B). 
In contrast, the phosphorylation status of Lyn at its negative regulatory site and its 
quantification showed an increase phosphorylation at Y-508 in PEP-/- BMMC 
compared to PEP+/+ BMMC (Figs 3.4C and 3.4D). In both the phosphorylation 
blot and the quantification, a higher level of Y-508 phosphorylation was seen in 
the PEP-/- compared to the PEP+/+ BMMC in the absence of IgE crosslinking. 
This is due to the presence of Csk at the lipid raft in the PEP-/- BMMC even in the 
resting/ unstimulated cells (Figs 3.2C and 3.2D).  
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Thus the observed increase in Cbp/PAG phosphorylation and thereby recruitment 
of Csk to the lipid rafts in the absence of PEP leads to inhibition of Lyn kinase 
activity by Csk which implicates a positive regulatory role of PEP in this signaling 
event. 
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Fig 3.4 PEP deficiency inhibits enzymatic activity of Lyn - (A) 8-10 x 106 PEP+/+ and PEP-/- 
BMMC are treated with anti-DNP IgE (1µg/ml) for 2 h and activated with DNP-HSA (200 ng/ml) for indicated time 
points. Cell lysates were immuno-precipitated with anti-Lyn antibody and its enzymatic activity was determined by 
an in-vitro kinase assay using enolase as substrate, followed by immunoblotting with phospho-Lyn (Y-397) antibody 
and then the filter was stripped and reprobed with anti-Lyn antibody. (B) The bar charts are the densitometric 
quantification of the signals of the kinase activity and phosphorylation signals. They represent mean ±S.E.M of 3 
independent experiments ***, p≤0.001) as well as densitometry analysis of phospho-Lyn immunoblot normalized to 
the amount of protein immunoprecipitated (n=3, ***, ≤p=0.005). (C) Cell lysate from above immunoprecipitation 
were probed for phosphorylation at Y-508 using a phospho-Lyn (Y-508) antibody and then reprobed with anti-Lyn 
antibody.  (D)  The results of three independent experiments as in C and presented in a bar chart as mean ± S.E.M 
(n=3**, ≤p=0.02).  
 
3.5 Differential regulation of LAT phosphorylation in the absence of PEP 
Signaling by Lyn leads to phosphorylation of phospholipid scramblase 1 
(PLSCR1) and LAT which in turn leads to calcium release from intracellular stores 
that eventually induce calcium influx (Amir-Moazami et al., 2008). As the Lyn 
kinase activity is reduced in the absence of PEP, it is expected that the downstream 
signaling pathways will also be down-regulated. To determine this, tyrosine 
phosphorylation of PLSCR1 and LAT were compared in PEP+/+ and PEP-/- 
BMMC following IgE crosslinking. 
Phosphorylation of PLSCR1 was determined by immunoprecipitation of PLSCR1 
followed by immunoblotting with phospho-tyrosine antibody and then reprobed 
with anti-PLSCR1antibody. Both basal and antigen-mediated transient increase in 
phosphorylation of PLSCR1 seen in PEP+/+ BMMC was significantly reduced in 
PEP-/- BMMC (Fig 3.5A, compare lanes 1-4 and 7-10). Quantification of the 
signals in 3 different experiments confirmed this reduction in phosphorylation (Fig 
3.5B).  
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Phosphorylation of LAT at Tyr 
136
 and Tyr 
195
 is essential for the binding and 
activation of PLCγ-1 and Grb2 respectively (Takeuchi et al., 2000). To investigate 
which of these two signaling pathway is affected by PEP knock-out, LAT tyrosine 
phosphorylation at the two sites was analyzed in LAT immunoprecipitates from 
PEP+/+ and PEP-/- BMMC. Phosphorylation  of LAT at Tyr
136
 needed for PLCγ-
1signaling (Saitoh et al., 2000) was reduced in PEP-/- BMMC when compared to 
PEP+/+BMMC (Figs 3.5C and 3.5D ) though phosphorylation slightly increases at 
20 min  in PEP-/- BMMC but it not that significant as seen in PEP+/+ BMM, while 
phosphorylation of LAT at Tyr
195
 needed for Grb2-ERK activation (Saitoh et al., 
2003) remained unaltered in the PEP+/+ and PEP-/- BMMC (Figs 3.5E and 3.5F). 
The results of the different effects of the absence of PEP in these signaling 
pathways were confirmed by quantification of the signals (Figs 3.5D and 3.5F)  
 
 





Fig 3.5 Reduced tyrosine phosphorylation of PLSCR1 and LAT in the absence of PEP - (A) 
5-6×10
6 
PEP+/+ and PEP-/- BMMCs cells were sensitized with anti-DNP IgE (1µg/ml) for 2 h and activated with 
DNP-HSA (200 ng/ml) for the indicated time points and then immunoprecipitated with anti-PLSRC1 antibody and 
immunoblotted with anti-phosphotyrosine antibody. After stripping, the filter was reprobed with anti-PLSRC1 
antibody. (B) Quantification of PLSCR1 phosphorylation was performed by densitometry analysis after 
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normalizing with the amount of protein immunoprecipitated and data represented as mean ± S.E.M (n=3, **,p≤0.05) 
(C) and (E) For LAT phosphorylation, the lysates  from PEP+/+ and PEP-/- BMMC were immunoprecipitated 
with anti-Lyn Ab and then subjected to western blot analysis and the membranes were immunoblotted with 
phospho-specific Abs that recognize the indicated phosphorylated tyrosine residues in LAT and anti-LAT for 
loading control. (D) and (F) Densitometric quantification was used to determine the relative intensity level of the 
phosphorylation signals and represented as mean ± S.E.M  (n=3,***p≤0.001)  
 
3.6 Effect of PEP deficiency on Ca
2+
, calcineurin/NFAT signaling pathway  
Aggregation of FcεRI receptors during mast cell activation coupled with calcium 
mobilization activates the calcium/calcineurin/NFAT pathway leading to 
production of inflammatory cytokines and lipid mediators (Monticelli et al., 2004; 
Yang et al., 2009) .  
Receptor ligation leads to the activation of phospholipase Cγ1 (PLCγ1), which 
hydrolyses phosphatidylinositol-4, 5-bisphosphate to produce inositol-1, 4, 5-
trisphosphate (InsP3) and diacylglycerol. InsP3 binds to IP3 receptors (IP3R) in 
the endoplasmic reticulum and induces release of calcium from intracellular stores 
which triggers the opening and promotes Ca
2+
 entry through calcium-release-
activated calcium (CRAC) channels in the plasma membrane such that the 
increased levels of intracellular calcium are maintained (Putney and Bird, 1993). 
Calcium binds to calmodulin, which in turn activates the calmodulin dependent 
serine phosphatase calcineurin. This enzyme dephosphorylates NFAT (nuclear 
factor of activated T cells), a transcriptional activator located in the cytosol of 
unstimulated cells in its phosphorylated form but translocate to the nucleus when 
dephosphorylated by calcineurin to induce the expression of NFAT-regulated 
genes (Fig 3.6.1) 





Fig 3.6.1 The Ca
2+
/ calcineurin/NFAT signaling pathway - NFAT is activated by cell-surface 
receptors coupled to Ca
2+
 mobilization. [Ca2+]i increases result in activation of many calmodulin (CaM)-dependent 
enzymes, including the phosphatase calcineurin . Calcineurin dephosphorylates multiple phosphoserine on NFAT, 
leading to its nuclear translocation and activation. Adapted from (Dolmetsch et al., 2001) 
 
PEP -/- BMMC has been shown to have reduced phosphorylation of PLCγ1 and 
calcium mobilization when compared to PEP+/+BMMC (Obiri et al., 2011), which 
can be explained by the reduced Lyn mediated activation of LAT at Tyr
136 
,the 
binding site of PLCγ1 seen in PEP-/- BMMC (Figs 3.5).  
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To determine the effects of reduced activation of Lyn/LAT/PLCγ-Ca
2+
 signaling 
pathway due to absence of PEP on the activity of the NFAT transcription factor,  
PEP wild-type and knockout BMMC were transfected with a plasmid containing 
multimerizsed NFAT binding sites driving the expression of a luciferase gene. 
These cells were sensitized with anti-DNP IgE and activated with DNP-HSA for 8 
h. A significant decrease in NFAT luciferase activity was seen in both in basal as 
well as after DNP-HSA stimulation in PEP deficient BMMC compared with that in 
wild-type BMMC (Fig 3.6.2A).  
Transfection of an IL-6 promoter-luciferase construct, known to be dependent on 
calcium, in BMMC (Tanaka et al., 2005), also produced similar results in that both 
basal as well as  antigen induced luciferase activity was significantly less in PEP-/- 
BMMC compared to PEP+/+ BMMC (Fig 3.6.2B). In contrast, the activity of other 
transcription factors such as NF-κB and AP-1 that are also activated by IgE-
receptor aggregation but are not dependent on PLCγ/Ca
2+
 pathway did not show 
difference in the PEP+/+ and PEP-/- BMMC (Fig 3.6.2C and 3.6.2D). These 
results demonstrate that absence of PEP leads to reduced NFAT activity. 




Fig 3.6.2 Reduced NFAT activation in the absence of PEP - 6 - 8 x106 PEP+/+ and PEP-/- BMMC 
were transfected with 0.6μg of Renilla luciferase expression vector and 4.3μg of the reporter construct p3xNFAT- 
/IL-6-/NF-κB-/AP-1-luciferase. After 24 h, the cells were sensitized with anti-DNP IgE for 18 h. Cells were then 
stimulated with DNP-HSA (200ng/ml) for 8 h and firefly luciferase activity was measured and normalized to Renilla 
luciferase activity (A) NFAT activity (B) IL6 promoter activity (C) NF-κB activity and (D) AP-1 activity. Results 
are shown as bar charts and presented as mean ± SEM (n=3), ***p=0.0003, **p≤0.005 .PEP+/+ (open bars); PEP-/-
(closed bars)       
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To confirm a direct role of PEP on the activity of NFAT, PEP was reintroduced 
into PEP deficient BMMC to see whether the decreased activity of NFAT in the 
knockout cells could be rescued. As a control PEP was also introduced into 
PEP+/+ BMMC. Transfection of a PEP expression vector into PEP-/- BMMC 
significantly increased both the basal and antigen induced NFAT activation. NFAT 
activity in DNP stimulated PEP-/- BMMC expressing PEP was equivalent to 
NFAT activity in PEP+/+ BMMC transfected with empty vector (Fig 3.6.3A). 
Overexpression of PEP in PEP+/+ BMMC show a further increase in NFAT 
activity (Fig 3.6.3A).  
The expression of PEP in transfected PEP knock-out and control wild-type BMMC 
was assessed by performing Western blot analysis (Fig 3.6.3B). These experiments 
clearly demonstrate that over expression of PEP, not only increase NFAT 
expression in wild-type BMMC but can also rescue the reduced activity of this 
transcription factor in PEP knock-out BMMC.  
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Fig 3.6.3 Reconstitution of PEP expression in PEP-/- BMMC - (A) 8-10 × 106 PEP+/+ and PEP -/- 
BMMCs were transfected with 0.6μg Renilla Luciferase expression vector and 4.3μg NFAT-luciferase reporter 
construct and additionally 4.3μg PEP-pCMV vector or an empty expression vector was transfected. After 24 h, the 
cells were sensitized with anti-DNP-IgE for 18 h. Cells were stimulated with DNP-HSA (200ng/ml) for 8 h and 
firefly luciferase activity was measured and normalized to Renilla luciferase activity. Results are presented as mean 
± SEM (*p≤0.01, **p=0.007, ***p≤0.0001, n=5) .PEP+/+ (open bars); PEP-/- (closed bars). (B) PEP+/+ and PEP-/- 
BMMCs were treated as shown in the figure and cell lysates were immunoblot using an anti-PEP specific antibody, 
and βactin as a loading control. 
 
To further demonstrate that it is not only the level of PEP but its activity that 
controls the action of NF-AT, two known inhibitors of PEP activity C28 and 
L75N04 were used in the NFAT activity assay.  
C28 is a gold (I) phosphine complex (Bis (2-cyanoethyl) phenylphosphine-Au(I)-
Cl) that selectively inhibits protein tyrosine phosphatases (PTP) through direct 
interaction with the catalytic cysteine residues (Karver et al., 2010). L75N04 (He et 
al., 2013)  is benzofuran salicylic acid-based that interacts with the phosphate-
binding pocket (catalytic pocket) of Lyp through its benzofuran salicylic acid 
moiety whereas the distal naphthalene ring interacts with a nearby peripheral site. 
Treatment of PEP+/+ BMMC with 5μM C28 reduced the antigen induced 
activation of NFAT as well as IL-6 response but not to the level of expression in 
PEP-/- BMMC. Moreover C28 had no effect on the basal activity in 
PEP+/+BMMC. C28 treatment did not alter the activation level of NFAT and IL-6 
in PEP-/- BMMC (Figs 3.6.4A and 3.6.4B). Higher concentration of C28 was not 
used to further down modulate NFAT/IL-6 activity because they were found to be 
toxic.  
Treatment of the PEP+/+ BMMC with L75N04 showed a dose dependent down-
regulation of both the basal and the antigen-mediated increase in NFAT/IL-6 
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luciferase activity. Though 5µM L75N04 was superior to the same concentration 
of C28, 20µM of the compound was found to be highly efficacious in inhibiting 
the PEP activity with no changes observed in PEP-/-BMMC (Figs 3.6.4A and 
3.6.4B).  Neither C28 nor L75N04 altered the NF-κB and AP-1 luciferase activity 
determined in both wild-type and PEP deficient BMMC (Figs 3.6.4C and 3.6.4D). 
Since no significant effect of both the inhibitors C28 and L75N04 was observed on 
the residual NFAT/IL-6 activity in the PEP-/- BMMC, this suggests that both 
compounds function by inactivating the activity of PEP. Additionally, a control 
immunoblot showed that both inhibitors did not alter the level of expression of 
PEP (Fig 3.6.4E) indicating that they indeed function through inhibition of activity 
of the PEP. 
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Fig 3.6.4 NFAT and IL-6 activation in the presence of Lyp/PEP inhibitors - 8x106 PEP+/+ and 
PEP-/- BMMC were transfected with 4.3μg 3xNFAT- /IL-6 /NF-κB / AP-1 luciferase plasmid  and 0.8μg of Renilla 
luciferase expression. 24 h after transfection, the cells were sensitized with anti-DNP IgE for 18 h.  Cells were 
treated with C-28 (5μM) or L75N04 (5 µM, 20μM) for 1 h to the end of IgE incubation. Cells were then activated 
with DNP-HAS (200 ng/ml) for 8 h and firefly luciferase activity was measured and normalized to Renilla luciferase 
activity. (A) NF-AT activity (B) IL6 promoter activity (C) NF-κB activity (D) AP-1 activity. Results in bar charts 
are presented as the mean ± SEM (***p≤0.0001, **p≤0.005, n=3). (E) PEP+/+ BMMC were treated as described 
above and cell lysates were immunoblotted using an anti-PEP antibody, anti-Lyn antibody and an anti- βactin 
antibody for loading control. Presented is a representative result of three independent experiments PEP+/+ (open 
bars) and PEP-/- (closed bars). 
 
3.7 Nuclear accumulation of NFATc1 opposed by the increased activation of 
JNK signaling pathway in PEP deficient BMMC 
NFAT family members comprising of four proteins (NFATc1-c4) are  expressed in 
mast cells where they regulate the transcription of  cytokines (Hock and Brown, 
2003; Hutchinson and McCloskey, 1995). 
Calcineurin mediated dephosphorylation and nuclear translocation of NFAT as 
shown in Fig 3.6.1 are counteracted by NFAT kinases such as JNK1, which act to 
phosphorylate NFAT proteins, thereby directly antagonizing their nuclear 
translocation by phosphorylating Serine-Proline repeats present in the motif (Beals 





thus  inhibiting calcineurin to bind the calcineurin targeting domain of NFATc1 
which is required for the regulation of both nuclear accumulation and 
transcriptional activity (Chow et al., 2000).   
We have previously reported (Obiri et al., 2011) and has again been shown in this 
thesis (Fig 3.7.1 A, compare lanes 7-12 with lanes 1-6), that PEP deficient BMMC 
show sustained phosphorylation of JNK1/2 . To determine the consequences of this 
sustained JNK phosphorylation in PEP-/- BMMC the phosphorylation status of 
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NFATc1 at Ser 
117
 and Ser 
172
 was studied by immunoprecipitating the cell lysates 





-NFATc1 antibodies. PEP-/- BMMC showed a 
significant and sustained increase in phosphorylation at these sites when compared 
to PEP+/+ BMMC (Figs 3.7.1B compare lanes 7-12 with 1-6). 
To investigate whether the sustained JNK1 signaling leads to down-regulation of 
the nuclear localization of NFATc1 in PEP deficient BMMC compared to wild-
type BMMC, cell fractionation studies were carried out to detect the presence of 
NFATc1 in the nucleus of these cells. Cytosol and nuclear extracts were isolated 
from PEP-/- and PEP+/+ BMMC which were sensitized by IgE and stimulated 
with DNP for 30 min and the presence of NFATc1 in the different cellular 
localizations was detected by Western blotting using βactin as a marker for the 
cytoplasm and histone H2A, a  marker for the nucleus. NFATc1 was detected both 
in nuclear and cytoplasmic fraction of PEP+/+ BMMC with antigen-receptor 
crosslinking leading to an enrichment of the signal in the nuclear fraction and a 
slight decrease in the cytoplasmic fraction. In comparison hardly any NFATc1 is 
detectable in nuclear extracts of PEP-/- BMMC not even after IgE receptor 
crosslinking (Fig 3.7.1C). These observations correlate with the enhanced 
phosphorylation of JNK1/JNK2. 
To confirm that JNK signaling  does contribute to the impaired NFAT activity 
observed in the PEP-/- BMMC, wild-type and kinase-deficient JNK1 and JNK2 
mutants (Kallunki et al., 1994) were co-transfected in wild-type and PEP knockout 
BMMC along with the NFAT luciferase plasmid and the activity of NF-AT was 
determined. While the wild-type JNK constructs down-regulated basal and 
significantly the antigen induced NFAT luciferase activity in PEP+/+ BMMC, the 
dominant negative constructs enhanced the NFAT activity in both types of BMMC 
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(Fig 3.7.1D). Intriguingly NFAT activity that is already low in PEP-/- BMMC 
could be further reduced by the wild-type JNK1 and JNK2 while the dominant 
negative kinase deficient JNKs enhanced NFAT activity albeit not to the same 
level as in the PEP+/+ BMMC (Fig 3.7.1D). Thus sustained JNK activity in PEP 
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Fig 3.7.1 Phosphorylation by JNK inhibits NFAT activation in PEP deficient BMMC - (A) 
3x10
6
 BMMC from PEP+/+ and PEP-/- mice were sensitized for 2 h with 1μg/ml anti-DNP IgE and then stimulated 
with 200 ng/ml DNP-HSA for the times indicated. Cell lysates were immunoblotted using the indicated specific 
phospho-JNK1/2 antibodies and β-actin as loading control. The results are representative of three separate 
experiments. (B) Cell lysates from PEP+/+  and PEP-/- BMMC were stimulated for stipulated time period and then 





antibody and then stripped and reprobed with  anti-NFATc1 antibody. (C) Nuclear extracts were prepared from 5-
10×10
6
 PEP+/+ and PEP-/- BMMC after they were left unsensitized or sensitized with 1μg/ml of anti-DNP IgE  and 
then stimulated with 200 ng/ml DNP-HAS for 30 min. The precipitated protein was immunoblotted with anti-
NFATc1 antibody. βactin and Histone2A were used as markers for cytosol and nuclei. Presented is a representative 
result of three independent experiments. (D) 6-8 x10
6
 PEP+/+ and PEP-/- BMMC were transfected  with 0.6μg of 
Renilla luciferase expression vector and 4.3μg 3×NFAT promoter luciferase reporter construct along with 2μg of 
3×HA-SRα JNK1 / 3×HA-SRα JNK1-APF / 3×HA-SRα JNK2 / 3×HA-SRα JNK2-APF. After 24 h, the cells were 
sensitized with anti-DNP-IgE for 18 h. Cells were stimulated with DNP-HSA (200 ng/ml) for 8 h. Firefly luciferase 
activity was measured and normalized to Renilla luciferase activity. Results are presented as the mean ± SEM 
((***p≤0.001, n=3). PEP+/+ (open bars); PEP-/-(closed bar) 
 
To verify the observed effects on JNK signaling which affects the nuclear 
accumulation of NFATc1 is indeed due to the absence of PEP and that it positively 
modulates this signaling pathway, Lyp/PEP inhibitor L75N04 was used in the 
experiments.  
Cell lysates were prepared from PEP+/+ BMMC after having been treated with 
20μM L75N04 and analyzed for JNK1/2 phosphorylation as well as for 





Similar to PEP-/- BMMC, wild-type BMMC treated with L75N04 showed 
enhanced and sustained phosphorylation of JNK1/2 as well as of NFATc1 at the 
above mentioned phosphoserine residues (Figs 3.7.2A and 3.7.2B, compare lanes 
1-6 with 7-12).  
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Also cell fractionation studies in presence of L75N04 revealed decreased or 
negligible amount of NFATc1 in the nuclear extracts of PEP+/+ BMMC treated 
with 20μM L75N04 (Fig 3.7.2C). 
These results demonstrate that this inhibitor mimics the PEP deficiency in the 
activation of JNK kinase and thereby resulting in decreased accumulation of 
NFATc1 in the nucleus of these cells. Additionally transfection experiments 
carried out with wild type JNK1/2 and dominant negative JNK-APF1/2 kinase 
deficient mutants in the presence of inhibitor in the wild type showed similar 
results as in the case of the PEP-/- BMMC. They showed reduced NFAT luciferase 
activity which can be more or less comparable to PEP deficient BMMC (Fig 
3.7.2D).  
Taken together these findings suggest that L75N04 is potent in inhibiting the 
activity of PEP and thereby inducing effects similar to PEP -/- BMMC on JNK 
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Fig 3.7.2 Lyp/PEP inhibitor L75N04 inhibits NFATc1 activation in wild-type BMMC- (A) 
3x10
6
 BMMC from PEP+/+ were sensitized for 2 h with 1μg/ml anti-DNP IgE and left either treated or untreated 
with 20μM L75-NO4 for 1 h  to the end of IgE incubation and then stimulated with 200 ng/ml DNP-HSA  for the 
times indicated. Cell lysates were immunoblotted using the indicated specific phospho-JNK1/2 antibodies and β-
actin as loading control. The results are representative of three separate experiments. (B) Cell lysates from PEP+/+ 
and PEP+/+ BMMC treated with 20μM L75-NO4 for 1 h were stimulated for stipulated time period and then 





antibody and anti-NFATc1 antibody as a control. (C) Nuclear extracts were prepared from 5-10×10
6
 PEP+/+ and 
PEP+/+ BMMC treated with L75N04 for 1 h and then stimulated with 200 ng/ml DNP-HAS for 30 min. The 
precipitated protein was immunoblotted with anti-NFATc1 antibody. βactin and Histone2A were used as markers 
for cytosol and nuclei. Presented is a representative result of three independent experiments. (D) 6-8 x106 PEP+/+  
treated with 20μM L75-NO4 for 1 h were transfected  with 0.6μg of Renilla luciferase expression vector and 4.3μg 
3×NFAT promoter luciferase reporter construct along with 2μg of 3×HA-SRα JNK1 / 3×HA-SRα JNK1-APF / 
3×HA-SRα JNK2 / 3×HA-SRα JNK2-APF. After 24 h, the cells were sensitized with anti-DNP-IgE for 18 h. Cells 
were stimulated with DNP-HSA (200 ng/ml) for 8 h. Firefly luciferase activity was measured and normalized to 
Renilla luciferase activity. Results are presented in the graph as the mean ± SEM (***p≤0.0001, **p≤0.005, n=3) 
PEP+/+ (open bars); PEP+/+ (20μM L75N04) (checkered bars) 
 
3.8 Inhibition of IgE-induced proximal signaling events by L75-NO4 in wild-
type BMMC 
Attenuation of NFAT activation by L75N04 in wild-type BMMC, suggests that 
this inhibitor can be used to unravel the events in the early signal pathway of mast 
cells to answer the question as to how the activity of PEP affects FcεRI signaling 
and not its presence or interaction with other proteins. Data already established in 
this work  (Section 3.2, 3.3 and 3.4) suggest a positive role of PEP in Lyn-
mediated signaling by dephosphorylating Cbp/PAG protein and thereby decreasing 
the recruitment of negative regulator Csk to the lipid rafts to Lyn.  
To identify PEP as a potential Cbp/PAG phosphatase, Cbp/PAG phosphorylation 
was monitored in PEP+/+ BMMC in presence and absence of L75N04 by 
immunoprecipitating the cell lysates with anti-Cbp/PAG antibody and probing 
them with anti-phosphotyrosine antibody. Hyper-phosphorylation of Cbp/PAG was 
observed in presence of the inhibitor in the wild-type BMMC as previously shown 
(Section 3.3) in PEP-/- BMMC (Fig 3.8.1A, compare lanes 7-12 with lanes 1-6).  
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Similar to PEP-/-BMMC, L75N04 treated wild-type BMMC showed 
phosphorylation of Cbp/PAG in the absence of antigen (Fig 3.8.1A, compare lane 
1 with 7), this suggest that L75N04 might be inhibiting the binding of PEP with 
Csk and Cbp/PAG. 
To investigate whether PEP binds to Cbp/PAG and as phosphorylation of 
Cbp/PAG leads to its interaction with Csk (Ohtake et al., 2002b; Takeuchi et al., 
2000), co-immunoprecipitation assay was performed to determine association of 
Csk with Cbp/PAG from the L75N04 treated PEP+/+BMMC. Lysates from 
PEP+/+ BMMC treated with or without L75N04 (20μM) were immunoprecipitated 
with either Cbp/PAG antibody or PEP antibody and then subjected to immunoblot 
analysis and probed with PEP, Csk and Cbp/PAG antibody.  
PEP immunoprecipitates from wild-type BMMC treated with L75N04 showed no 
interaction with Cbp/PAG and Csk in presence of antigen, also the constitutive 
interaction of PEP with Csk is lost in presence of this inhibitor (Fig 3.8.1B, 
compare lanes 9-10 with lanes 3-4) indicating that an active PEP is required to 
bind to Csk and Cbp/PAG.  
Cbp/PAG immunoprecipitates in the absence of inhibitor there was interaction with 
PEP and Csk following antigen crosslinking in PEP+/+ BMMC, in the presence of 
L75N04 there was no interaction with PEP as shown above (Fig 3.8.1C compare 
lane 10 with lane 4). There was however an increased interaction of Cbp/PAG with 
Csk even in the absence of antigen crosslinking in the treated BMMC (Fig 3.8.1C 
compare lanes 9-10 with lanes 3-4). This increased interaction of Csk with 
Cbp/PAG in presence of inhibitor suggest that the recruitment of Csk is influenced 
by the presence of inhibitor , to investigate whether inhibition of PEP activity does 
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have a role in this process a sucrose gradient centrifugation assay was carried out 
in PEP+/+BMMC treated without or with the Lyp/PEP inhibitor L75N04.  
In PEP+/+BMMC about 40% Csk remained in the lipid rafts with Cbp/PAG after 
IgE crosslinking (Figs 3.8.1D left panel and 3.8.1E) while in L75N04 treated 
PEP+/+ BMMC, around 60-70% increased recruitment of Csk into the lipid rafts 
was observed (Figs 3.8.1D right panel and 3.8.1E). Under the same conditions 
although 40% PEP was in the lipid rafts in IgE/DNP activated cells (Figs 3.8.1D 
left panel and 3.8.1E), in the presence of the inhibitor, hardly any PEP is seen in 
the rafts fraction. The majority of PEP seems to remain in the soluble fraction (Figs 
3.8.1D right panel and 3.8.1E).   
This enhanced recruitment of Csk to the lipid rafts in presence of inhibitor suggest 
a possible higher negative regulation of Lyn activity as seen in PEP-/- BMMC 
which might explain the potency of L75N04 in attenuating the NFAT activation.    
Experiments presented in this thesis on PEP deficient BMMC have demonstrated 
that an enhanced recruitment of Csk into the lipid rafts results in inhibition of Lyn 
activity through an increased phosphorylation at its negative regulatory site. A 
similar effect is expected if the activity of PEP is required for this effect. In-vitro 
kinase assay as well as phosphorylation on both positive (Y-397) and negative (Y-
508) regulatory site of Lyn were determined in the absence and presence of 
L75N04 in wild-type BMMC after IgE receptor crosslinking. 
Lyn activation in PEP+/+BMMC treated with L75N04 was determined by the PTK 
(Protein Tyrosine Kinase) activity towards the exogenous substrate enolase in the 
in-vitro kinase assay. Lyn immunoprecipitates from PEP+/+BMMC treated 
without or with L75N04 were incubated with 1mM ATP and 30μl of prepared 
substrate (acid-denatured enolase) for 2 h  at 37°C  and then subjected to 
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immunoblot analysis and then probed with anti-phosphotyrosine antibody to detect 
the phosphorylation of Enolase. Phosphorylation status of Lyn at sites Y-508 and 
Y-397 was determined by using same Lyn immunoprecipitates and probing them 
with specific phospho-Lyn antibodies. 
Wild-type BMMC show reduced Lyn-PTK activity (reduced phosphorylation of 
enolase) in presence of inhibitor, indicating that the chemical inhibition of PTPase 
(Protein Tyrosine Phosphatase) activity of PEP causes suppression of Lyn activity 
(Fig 3.8.2A compare lanes 7-12 with lanes 1-6). Moreover Lyn 
immunoprecipitates from PEP+/+ BMMC treated with L75N04 show reduced 
phosphorylation at Tyr
397
compared to non-treated PEP+/+ BMMC (Fig 3.8.2A 
compare lanes 7-12 with lanes 1-6). Quantification of the kinase assay and the 
Tyr
397
 activity also represents the significant reduction seen in L75N04 treated 
PEP+/+BMMC (Fig 3.8.2B). The phosphorylation status of Lyn at its negative 
regulatory site and its quantification showed an increase phosphorylation at Tyr
508
 
in L75N04 treated PEP+/+BMMC compared to PEP+/+ BMMC. 
These findings suggest that the inhibition of phosphatase activity of PEP does not 
only affect the NFAT activation pathway but also targets the proximal mast cell 
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Fig 3.8.1 L75-NO4 enhances recruitment of Csk to the lipid rafts - (A) Cell lysates from PEP+/+ 
were sensitized with anti-DNP IgE (1μg/ml) for 2h and then left untreated or treated with L75-NO4 (20μM) for 1h 
to the end of IgE incubation, then stimulated with DNP-HAS(200ng/ml) for 30 min. Lysates were 
immunoprecipitated with anti-Cbp/PAG antibody and immunoblotted to probe for phosphotyrosine, the filter was 
stripped and reprobed with anti-Cbp/PAG antibody (B) and (C) PEP+/+BMMCs cells were treated with anti-DNP 
IgE (1µg/ml) for 2 h and activated with DNP-HSA (200 ng/ml) in the presence and absence of inhibitor .Cell lysates 
were immuno-precipitated with anti-PEP or anti-Cbp/PAG antibody  and subjected to immunoblot analysis with 
anti-PEP, anti-Csk and anti-Cbp/PAG antibodies. (D) Cell lysates (non-stimulated and stimulated) from wt BMMCs 
in presence and absence of inhibitor were subjected to sucrose gradient centrifugation and lipid rafts fractions were 
isolated. PEP and Csk content of raft or non- rafts fractions isolated was visualized by immunoblotting with 
respective antibodies. An anti-Cbp/PAG antibody serves as a marker of Lipid rafts. (E) The graph represents the 
densitometric quantification of amount of Csk and PEP present in rafts and non-rafts (soluble) fractions from 3 
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Fig 3.8.2 Lyn activation is impaired in presence of L75-NO4 in wild type BMMC- (A) 8-10 x 
10
6
 PEP+/+  were treated with anti-DNP IgE (1µg/ml) for 2 h and  left untreated or treated with L75-NO4 (20μM) 
for 1 h to end of IgE incubation and then activated with DNP-HSA (200 ng/ml) for indicated time. .Cell lysates were 
immuno-precipitated with anti-Lyn antibody and its enzymatic activity was determined by in-vitro kinase assay 
using Enolase as substrate, as well as immunoblotted with phospho-Lyn(Y-397)Ab  (B) The graph represents the 
densitometric quantification of kinase activity determined in  in vitro kinase assay.(mean of 3 independent 
experiments, ***p≤0.005) as well as densitometry analysis of phosphor-Lyn immunoblot normalized to the amount 
of protein immunoprecipitated (n=3, ***p≤0.001). (C) Cell lysate from above immunoprecipitation were probed for 
phospho-Lyn(Y-508) Ab that recognizes the indicated phosphorylated tyrosine residues in Lyn. The results of three 
independent experiments as in C, were quantified by densitometry analysis (n=3, ***p≤0.0002).  
 
3.9 Effect of PEP deficiency on mast cell degranulation 
Activated mast cells promote allergic inflammation following the release of 
biochemical mediators (Bischoff, 2007). IgE mediated signaling through the LAT-
PLCγ-Ca2+ pathway does not only end up in activation of the activity of NF-AT 
but also leads to degranulation. Degranulation occurs through the process of 
exocytosis whereby cargo proteins and other molecules are loaded into vesicles 
and shuttled to different subcellular locations for fusion events. It results in the 
release of preformed mediators like β-hexosaminidase, serotonin, neural proteases 
and, histamine from the mast cell granules which causes an increase in vascular 
permeability, bronchoconstriction and inflammatory reaction in the mucosa. 
To investigate the impact of PEP gene deletion as well as inhibition of its 
enzymatic activity by L75N04 on the capacity of mast cells to degranulate, amount 
of β-hexosaminidase released was measured. 
BMMC from PEP+/+ and PEP-/- mice were sensitized with IgE and left non-
treated or treated with L75N04 (20μM) and then stimulated with DNP. Cells were 
suspended in Tyrode’s buffer +0.1% TritonX-100 for complete lysis and then 
centrifuged. Supernatants were then subjected to spectrophotometric quantification 
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of the released hexosaminidase using fluorescent N-acetyl-β-D-glucosaminidase as 
a substrate, as a measure for degranulation. 
The results show significant difference in the percentage of hexosaminidase 
released between the wild-type and PEP deficient BMMC. PEP-/- BMMC showed 
~ 2 2-fold reduced reduction in degranulation compared to PEP+/+ BMMC at 30 
min DNP stimulation (Fig 3.9.A). Overall PEP-/- BMMC showed lower capacity 
to degranulate. 
As seen in the regulation of NF-AT activity, 20μM of L7N04 was able to reduce 
degranulation by ~ 1.7 fold at 30 min DNP stimulation in PEP+/+BMMC. Even at 
other time points, the amount of β-hexosaminidase released was significantly 
reduced. Actually L75N04 treated PEP+/+ BMMC mimicked the effects of PEP-/- 
BMMC, as the amount of β-hexosaminidase released was similar in these BMMC.  
In contrast, L75N04 had no effect on the residual degranulation in PEP-/- BMMC. 
There was no difference in the amount of β-hexosaminidase released between the 
treated and untreated PEP-/- BMMC. 
To further verify a direct role of PEP in the degranulation process, BMMC from 
wild-type as well as from PEP deficient mice were transfected with pCMV-based 
vectors that express PEP to find out whether the defect in the PEP-/- BMMC could 
be rescued. Cells were sensitized with anti-DNP IgE and then stimulated with 
DNP-HSA. Cells were suspended in Tyrode’s buffer +0.1% TritonX-100 for 
complete lysis and then centrifuged. Supernatants were then subjected to 
spectrophotometric quantification of the released hexosaminidase using fluorescent 
N-acetyl-β-D-glucosaminidase as a substrate, as a measure for degranulation  
Transfection of the PEP expression vector into the PEP+/+ BMMC increased both 
the basal and antigen-induced degranulation (Fig 3.9B). More importantly over 
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expression of PEP in the PEP-/- BMMC significantly increased both the basal (~ 5 
fold) and the antigen induced (~ 2.5 fold) degranulation. Thus reconstitution of 
PEP-/- BMMC with PEP restored degranulation to levels similar to that seen in the 
empty vector transfected wild-type BMMC (Fig 3.9B).  
Control Western blot experiments with an anti-PEP antibody and a β-action 
antibody for loading control, show that the transfected PEP is indeed expressed in 
PEP-/- BMMC. This was more difficult to observe in the PEP+/+ BMMC that 
endogenously express PEP (Fig 3.9C).  Taken together these studies confirm that 
PEP is required for the degranulation of mast cells.  
Intriguingly, both PEP+/+ and PEP-/- showed some level of basal degranulation 
(Figs 3.9A and 3.9B), which suggest that some other pathway is activated in these 
BMMC apart from IgE-FcεRI signaling pathway which also leads to 
degranulation. As these BMMC are cultured in medium supplemented with SCF, 
Kit signaling pathway seems to be responsible for this process, since  it  is known 
that SCF not only enhances antigen mediated release of mediators but can itself 
stimulate degranulation, synthesis of inflammatory lipids when added to KL-
deprived mast cells (Gibbs et al., 1997; Taylor et al., 1995).  Hence effect of PEP 
deficiency on Kit signaling pathway was investigated by carrying out 
degranulation studies, wherein the amount of β-hexosaminidase released was 
measured.  
For this assay PEP-/- and PEP+/+ BMMC were deprived of SCF overnight and 
then stimulated with SCF at various concentrations for 30 min and then suspended 
in Tyrode’s buffer +0.1%TritonX-100 and then subjected to spectrophotometric 
quantification of the released hexosaminidase using fluorescent N-acetyl-β-D-
glucosaminidase as a substrate, as a measure for degranulation. 
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PEP+/+ BMMC showed enhanced degranulation ~ 8 fold from the basal level at 
400ng-SCF (Fig 3.9D), while PEP-/- showed only ~2.5 fold increased 
degranulation from basal level at 400ng (Fig 3.9D). The results reflect that indeed 
the ability of PEP-/-BMMC to degranulate when stimulated with SCF is 
compromised compared to PEP+/+BMMC as there is no significant difference in 
their basal level. Taking 400ng SCF as optimal concentration, the kinetics of 
degranulation was analyzed in PEP-/- and PEP+/+ BMMC. In PEP+/+ BMMC, 
degranulation  increases and reaches a peak at 20 min (~ 8 fold) and then it levels 
off at 30 min (Fig 3.9E), while in PEP-/- BMMC, release of hexosaminidase 
reaches a peak at 15min ( ~ 2 fold) and then rapidly decreases (Fig 3.9E). 
To confirm that the effects observed are indeed due to the absence of PEP, the 
degranulation assay were carried on PEP+/+BMMC treated with L75N0. IL-3 and 
SCF starved PEP+/+BMMC were pretreated with L75N04 (20μM) and then 
stimulated with 400ng SCF for indicated time points. The cells were then subjected 
to degranulation assay as described above.  
Wild-type BMMC treated with L75N04 showed similar degranulation kinetics as 
seen in PEP-/- BMMC. PEP inhibitor treated BMMC had significantly reduced 
amount of β-hexosaminidase released compared to non-treated PEP+/+BMMC. 
Inhibitor treated BMMC showed increase in degranulation at 15 min (~ 3 fold) and 
then subsided down, mimicking the effects seen in PEP-/-BMMC (Fig 3.9.F).  
Taken together, these results reflect that indeed phosphatase activity of PEP is 
required in both IgE-FcεRI mediated as well as in SCF-Kit activated mast cell 
degranulation.  
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Fig 3.9  β-Hexosaminidase release in PEP knock-out and L75N04 treated BMMC - (A) 5×106 
cells /ml  BMMC from PEP +/+ and PEP-/- mice were sensitized with anti-DNP-IgE(1μg/ml) for 16 h  and treated 
with L75N04 (20μM) for 1 h at the end of IgE incubation. These cells were then activated with DNP-HSA (200 
ng/ml) for various time points. BMMC were pelleted and the amounts of β-hexosaminidase in supernatant and in the 
solubilized pellet were measured using p-nitrophenyl N-acetyl-β-D-glucosaminidine (p-NAG) as substrate. Percent 
degranulation was calculated as follows: (released activity/total activity) ×100. The results are represented as mean 
of ± SEM of 3 independent experiments of % β hexosaminidase release for PEP+/+ (open bars), PEP-/- (closed bars) 
and L75N04 20μΜ (red bars) treated cells (**p≤0.05, ***p≤0.0005, n=3). (B) 8-10 × 10
6
 PEP+/+ and PEP -/- 
BMMCs were transfected with 4.3μg of PEP-pCMV vector or an empty expression vector. After 24 h, the cells were 
sensitized with anti-DNP-IgE for 2h. Cells were stimulated with DNP-HSA (200ng/ml) for 30 min and β-
hexosaminidase release was measured as described in (A). Results are presented as the mean ± SEM (*p≤0.01, 
***p≤0.0001, n=5).PEP+/+ (open bars); PEP-/-(closed bars). (C) PEP+/+ and PEP-/- BMMCs were treated as 
shown in the figure and cell lysates were immunoblot using an anti-PEP specific antibody, and actin as the loading 
control. Presented is a representative result of three independent experiments. (D) 8×10
6
 cells /ml  BMMC from PEP 
+/+ and PEP-/- mice were  cultures overnight in IL-3 and SCF depleted medium overnight  and then activated with  
SCF at different concentration for 30 min. BMMC were pelleted and the amounts of β-hexosaminidase in 
supernatant and in the solubilized pellet were measured using p-nitrophenyl N-acetyl-β-D-glucosaminidine (p-NAG) 
as substrate. Percent degranulation was calculated as follows: (released activity/total activity) ×100. The results are 
represented as mean of ± SEM of 3 independent experiments (***p≤0.005) of % β hexosaminidase release for 
PEP+/+ (open bars) and PEP-/- BMMC (closed bars). (E) 8-10 × 10
6
 PEP+/+ and PEP -/- BMMCs were cultured as 
described in (A) and then stimulated with SCF (400ng/ml) at  different time point as indicated in the figure and β-
hexosaminidase release was measured as described in (A). Results are presented as the mean ± SEM (***p≤0.0001, 
n=3) PEP+/+ (open bars); PEP-/- BMMC (closed bars). (F) 8×10
6
 cells /ml  BMMC from PEP +/+ mice were  
cultured overnight in IL-3 and SCF depleted medium overnight and left either untreated or treated with (20μM) 
L75N04 for 1 h and then activated with SCF (400ng/ml) at different time point. BMMC were pelleted and the 
amounts of β-hexosaminidase in supernatant and in the solubilized pellet were measured using p-nitrophenyl N-
acetyl-β-D-glucosaminidine (p-NAG) as substrate. Percent degranulation was calculated as follows: (released 
activity/total activity) ×100. The results are represented as mean of ± SEM of 3 independent experiments 
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3.10 IgE mediated gene expression profiles in wild-type and PEP deficient 
BMMC 
IgE-FcεRI crosslinking activates mast cell signaling pathways and ultimately leads 
to release of calcium and pro-inflammatory mediators (degranulation). PEP-/- 
BMMC have reduced activation of Lyn/LAT signaling and reduced release of β-
hexosaminidase. To determine whether PEP deficiency has other possible defects, 
RNA profiling was carried out using Affymetrix gene chip microarray analysis. 
Two conditions were used: (1) control/non-stimulated and (2) IgE/DNP stimulated 
for 30 min in wild-type and PEP deficient BMMC.  
Total RNA was extracted from 10 X 10
6
 cells from resting and activated WT and 
PEP-/- BMMC using TRIzol reagent. Further purification of RNA was done using 
the RNeasy kit (Qiagen). These RNA samples were then sent to Dr. Ludger Klein-
Hitpaß Lab (University Essen) where they performed micro-array analysis. 
Briefly, from 200ng of RNA, cDNA synthesis was performed followed by in vitro 
transcription of biotinylated complementary RNA. The labeled complementary 
RNA were hybridized to mouse gene array containing 14,000 probe sets 
(GeneChip Mouse Genome Array 430 2.0 Array) and analyzed with GeneChip 
Scanner. Affymetrix Statistical Algorithms (MAS5 algorithms) was used in the 
expression analysis of GeneChip probe arrays for background correction, 
normalization and calculation of gene expression values. This microarray analysis 
had no replicates as a result all the expression changes seen in this array were 
validated with realtime PCR. 
Total of 12,390 genes were reliable measured out of which 5046 genes were 
differentially regulated by IgE in wild type and PEP deficient BMMC. The results 
are expressed as the ratio between IgE stimulated over control; IgE/Ctrl >/< 1.5 
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fold, with red indicating an increase in signal and yellow indicating a lower signal. 
Heat maps were generated using Multiexperiment Viewer Software (Fig 3.10A). 
Importantly the figure illustrates that absence of PEP leads to positive and negative 
regulation of gene sets 
Out of 5406 genes showing differential regulation by IgE in wild type and PEP-/- 
BMMC, genes with a fold change cut of 2 for up-regulated genes and down-
regulated genes were selected and a Venn diagram was generated.  The Venn 
diagram illustrates that a large number of genes was up-regulated by IgE in 
presence of PEP while a comparatively reduced number was obtained in PEP-/- 
BMMC. In case of the repressed genes, only 2-fold difference was seen in the 
genes that are down-regulated by IgE in wild-type and PEP deficient BMMC (Fig 
3.10B).  
To assess the biological significance of this differential regulation of genes by IgE 
in PEP+/+ and PEP-/- BMMC, Gene Set Enrichment Analysis (GSEA) was used. 
GSEA makes use of the Molecular Signature Database (MSigDB) which contains 
more than 3000 gene sets for use with GSEA ordered into 5 gene set categories 
(c1-c5). Out of these categories c2 Biocarta gene set category is presented here 
which shows those biological processes that are up-regulated by IgE in wild-type 
and PEP knock-out mast cells with FWER p-value < 0.25 or FDR q-value < 0.01. 
The top 10 processes that showed lowest FDR (false discovery rate) q-value were 
selected (Fig 3.10C).  
In wild-type BMMC, pathways involved in inflammatory processes were up-
regulated while in PEP deficient BMMC pathways involved in microtubule 
formation were enhanced.  
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The differentially regulated genes showed some interesting functional clustering.  
For example the gene pool that showed down-regulation in the absence of PEP are 
genes that belong to calcium signaling pathways that include many cytokines 
involved in inflammatory processes. Heat map with selected genes that encode 
proteins involved in calcium signaling and downstream cytokine pathways was 
generated. The results are expressed as the ratio between IgE stimulated over 
control; IgE/Ctrl >/< 2 fold, with red indicating an increase in signal and yellow 
indicating a lower signal (3.10D).  
Heat map illustrated indicates that indeed absence of PEP down-regulates genes, 
whose expression is dependent on calcium for example IL-6, NFATc1, STIM 1 
and many inflammatory cytokines which are dependent on NFAT transcription 
factor (IL-4, IL-13 and IL-2). 
Since there were no replicates these data were considered as preliminary and to 
validate these findings real time PCR was performed. 
 
 













Fig 3.10 Comparison of IgE mediated gene expression profiles in wild-type and PEP 
deficient BMMC - (A) PEP+/+ and PEP-/- BMMC were left unstimulated or stimulated with IgE/DNP for 30 
min. Gene expression analysis was performed using Affymetrix mouse genome chip. Control (unstimulated cells) 
were used as baseline and results are expressed as ratio between IgE stimulated over control; IgE/Ctrl >/< 1.5-fold. 
Gene expression pattern was generated using Multi experiment viewer. (B) Venn diagrams were generated 
comparing genes with a fold change cutoff of 2 for induced and repressed genes using Multi experiment viewer. (C) 
Gene set enrichment analysis was performed to obtain the biological functions up-regulated in wild-type and PEP 
deficient BMMC after IgE/DNP stimulation. Top 10 processes with lowest FDR q-value (false discovery rate) are 
plotted. (D) Heat maps showing relative expression level of genes that encode proteins that are bound by calcium 
                                                                                                                                                                           Results 
98 
 
binding or protein with inflammatory functions. Control (unstimulated cells) were used as baseline and results are 
expressed as ratio between IgE stimulated over control; IgE/Ctrl >/< 2 -fold. Gene expression pattern was generated 
using Multi experiment viewer.     
 
3.11 Validation of microarray data- PEP regulates the expression of cytokine 
/chemokine genes and also genes that are involved in calcium/NFAT signaling 
pathway 
To validate some of the potential targets identified in the heat map that show 
differential regulation in wild-type and PEP deficient BMMC in the microarray 
analysis, quantitative real time PCR was carried out.  
RNA was extracted from PEP+/+ and PEP-/- BMMC which were sensitized with 
IgE/DNP and either left untreated or treated with 20μM L75N04 to generate 
“chemical knockdown” of PEP and the same treatment was used on PEP-/- BMMC 
as control. Quantitatively, the relative expression of these genes were measured in 
three independent experiments using primers for the respective genes and 
normalized against a transcript of the ribosomal subunit 36B4 gene that served as a 
control. 
 The first gene set to be analysed included genes that are implicated in the 
regulation of calcium /NFAT signaling pathway such as PLSCR1 (phospholipid 
scramblase-, IP3R (inositol-3-phosphate receptor) - these genes are involved in 
Lyn mediated calcium release from ER stores, STIM1 and Orai1 - controls the 
opening of CRAC channel for calcium influx, NFATc1 and PPP3CB - encodes 
NFAT transcription factor and its phosphatase calcineurin respectively. 
Expression of these genes in general was reduced in PEP deficient BMMC as well 
as wild-type BMMC treated with 20μM L75N04 Lyp/PEP inhibitor. The genes that 
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were drastically affected in PEP -/-BMMC were the NFATc1, STIM1 and Orai-1 
these genes showed no up-regulation even after stimulation. 
L75N04 treated BMMC showed reduced expression of all the genes, it also 
reduced the basal expression of PLSCR1, STIM1 and PPP3CB genes. PEP 
inhibitor not only showed effects on PEP+/+BMMC but it was able to reduce 
expression of genes such as PLSCR1 and PPP3CB in PEP-/- BMMC (Fig 3.11A). 
The other gene set that was analysed by realtime PCR included cytokines/ 
chemokines that were up-regulated by IgE/DNP stimulation as seen in microarray 
analysis and were either dependent on calcium/NFAT pathway or not dependent on 
this pathway. 
Cytokines /chemokines dependent on calcium /NFAT signaling pathway such as 
IL-2, IL-4, IL-6, IL-13, TNF-α  and CCL-12 showed increase in their expression 
level in wild-type BMMC after IgE/DNP stimulation while in PEP-/- BMMC , the 
expression level of these genes both basal and antigen induced, were lower when 
compared to wild-type BMMC (Fig 3.11B). 
L75N04 treated BMMC showed significant decrease in their expression level, 
genes such as CCL-12, IL-6 and IL-13 showed reduce expression even at the basal 
level in the presence of inhibitor in PEP+/+BMMC. In PEP-/- BMMC only IL-2 
expression level was reduced in the presence of inhibitor (Fig 3.11B). 
m-RNA expression level of cytokines/ chemokines that were not regulated by 
calcium/NFAT signaling pathway such as IL-1β, IL-10, CCL-2 and MIP-1α were 
enhanced after IgE/DNP stimulation in both PEP+/+ and PEP-/- BMMC. There 
was no significant difference in the expression level of these genes in the both the 
mast cells (Fig. 3.11C) 
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Moreover L75N04 did not have any effect on the expression level of these genes in 
both wild-type and PEP knock-out BMMC (Fig 3.11C).  
These results, which reflected the data obtained from Lyn/LAT/NFAT activation 
studies, confirmed that indeed PEP is essential for calcium/NFAT signaling 


















Fig 3.11 Cytokine/Chemokine gene expression - BMMC (2x106) were sensitized with 1μg/ml  anti- 
DNP IgE for 2 h and  left unstimulated or stimulated with 200 ng/ml DNP-HSA for 30 min in the absence or 
presence of inhibitors L75N04 (20μΜ). RNA was isolated from these cells, reverse transcribed into cDNA and 
subjected to real-time quantitative PCR. The expression of the cytokine/chemokine genes was measured using 
primers for the respective genes (A) PLSCR1, IP3R, STIM1, Orai1, NFATc1, PP3CB (B) IL-2, IL-4, IL-6,IL-
13,TNF-α, CCL-12 (C) IL-1β, IL-10, CCL-2, MIP-1α, and normalized against the level of expression of the 
ribosomal subunit 36B4 gene. (*p≤0.02, **p≤0.005, ***p≤0.0001, n=3) PEP+/+ BMMC (open bars) and PEP-/- 
BMMC (closed bars)  
 
 




3.12 L75N04 suppresses Passive Systemic Anaphylaxis in wild-type mice  
Aggregation of FcεRI by binding of FcεRI-bound IgE to multivalent allergen 
activates downstream events that lead to degranulation and synthesis of cytokines 
and chemokines, which in turn induces the pathophysiologic consequences of 
anaphylaxis (Galli et al., 2008). Release of vasoactive amines (such as histamine-a 
potent vasodilator), causes fall in body temperature, which can be monitored as an 
index of anaphylaxis after antigen stimulation.  
It has previously been reported by our laboratory that PEP-/- mice are less 
susceptible to passive systemic anaphylaxis compared to PEP+/+ mice which was 
in agreement with degranulation results obtained with PEP+/+ and PEP-/- BMMC 
(Obiri et al., 2011). As the Lyp/PEP inhibitor L75N04 is more potent in inhibiting 
IgE receptor signaling compared to C28, its efficacy in inhibiting passive systemic 
anaphylaxis was investigated. 
Wild-type and PEP deficient mice were sensitized with IgE, treated with vehicle 
alone (0.1% DMSO in PBS) or 5μM C28, or 20μM L75N04 and following 
intravenous injection of DNP, changes in body temperature were measured every 5 
min as a measure of anaphylaxis.  
The vehicle treated wild type mice were more susceptible to anaphylaxis than PEP 
deficient mice as previously reported (Obiri et al., 2011). C28 treated wild type 
mice rescued the anaphylactic response but no further than the level induced in 
PEP deficient mice (Figs 3.12A and 3.12 B, blue line). 
PEP+/+ mice treated with the inhibitor L75N04 showed a better rescue of 
anaphylaxis than C28, although its effect in the PEP-/- mice did not significantly 
differ from that of C28 (Figs 3.12A and 3.12B red line). These results confirm that 
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compound L75N04 is a more potent inhibitor of anaphylaxis than C28 and that its 
effect is mediated in part through the inhibition of the action of PEP.  
Together, the results show that L75N04 is capable of down-regulating calcium 
mediated transcription and degranulation in mast cells and inhibiting passive 
systemic anaphylaxis in mice. 
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Fig 3.12 Systemic anaphylaxis impaired in the presence of inhibitors - PEP+/+ and PEP-/-  mice 
were sensitized for 24 h with 1 mg/kg IgE and subsequently injected intra-peritoneal (IP) with either vehicle alone 
(0.01% DMSO-PBS) or C28 (5μM) or L75N04 (20μM) for 1 h to the end of the IgE incubation time. Anaphylaxis 
was induced with intra-venous injection of 200 μl DNP-HSA and the change in body temperatures measured every 5 
min for 1h. Change in body temperature for (A) PEP+/+ and (B) PEP-/- mice are shown in black (PBS), blue (C28) 
and red (L75N04) respectively. Results are presented as the mean ± SEM (n=5) 
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4.0 Discussions  
The manifestation of mast cell driven allergic reactions are considered to be mainly 
a consequence of the release of pro-inflammatory mediators following antigen-
induced aggregation of IgE-bound high affinity receptors for IgE (FcεRI) 
expressed on  the mast cell surface. The initial receptor-signaling involves 
phosphorylation of Src family tyrosine kinase Lyn /Syk. The subsequent Syk 
and/or Lyn-mediated tyrosine phosphorylation of the trans-membrane adaptor 
molecule LAT (linker for activation of T cells) is crucial for the downstream 
signaling required for the release of pro-inflammatory mediator (Gilfillan and 
Tkaczyk, 2006).  
The status of mast cell activation at any point in time is a balance between the 
signaling pathways discussed above and those that down-regulate these processes. 
For maintaining the homeostasis and the normal immune response, a dynamic 
equilibrium between protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatase (PTPs) is required. Deregulations in this equilibrium and alterations in 
the expression or activity of PTPs can have pathophysiological consequences 
resulting in autoimmune diseases, cancer and diabetes 
 LYP and its murine ortholog PEP is exclusively expressed in immune cells and is 
reported to be a negative regulator of T-cell receptor signaling wherein it 
suppresses the activity of Src-family kinases (Hasegawa et al., 2004). It has 
previously been reported that PEP is expressed in mast cells (Maier et al., 2007) 
and that bone marrow derived mast cells from PEP-/- mice show reduced calcium 
mobilization and PEP positively regulates IgE-mediated anaphylaxis in mice (Obiri 
et al., 2011). However the molecular mechanism underlying this effect of PEP is 
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still unknown. In this study the mechanisms involved in the positive regulation of 
IgE-mediated signaling by PEP in mast cells has been investigated. 
The present study provides an insight into the role of PEP in the regulation of 
FcεRI signaling, degranulation and cytokine production in BMMC. The results 
demonstrate that PEP primarily acts at a receptor-proximal level by regulating the 
recruitment of Csk-negative regulator of Src-family kinases like Lyn, to the lipid 
rafts by acting as a Cbp/PAG phosphatase. This regulation has proven to be 
essential for Lyn activation and downstream signaling events, since genetic 
ablation of PEP or the use of a pharmacological inhibitor of PEP showed inhibition 
of the protein tyrosine kinase activity (PTK activity) of Lyn resulting in the 
inhibition of phosphorylation of signaling molecules essential for Ca
2+
 influx (such 
as LAT). Additionally, degranulation mediated through both IgE-FcεRI and SCF-
Kit activation is down-regulated alongwith cytokine gene expression in mast cells 
which are deficient in PEP and those which are treated with the inhibitor. These 
findings reveal that PEP plays a major role in mast cell signaling.  
 
4.1 PEP functions as a Cbp/PAG phosphatase 
 
Several substrates of PEP have been described in T-cells using substrate-trapping 
experiments and GST pull down experiments (Wu et al., 2006). Similar studies 
have not been described for PEP in mast cells. In the work presented here, co-
immuprecipitation studies were carried out to identify putative targets of PEP in 
mast cells. The studies were concentrated on Src-like protein kinase and they 
revealed that PEP interacts with proximal signaling molecules involved in IgE-
mediated mast cell activation like Lyn and LAT only after antigen crosslinking of 
FcεRI receptor while it is associated with Csk before and after IgE receptor 
                                                                                                                                                                 Discussions 
109 
 
engagement. PEP deficient BMMC showed association of Csk with Lyn even 
under resting conditions which was not seen in wild-type BMMC. 
It has previously been reported that tyrosine phosphorylation of Src family kinase 
Lyn present in membrane domains (lipid rafts) initiates a signaling cascade leading 
to mast cell activation. Csk, a negative regulator of Lyn, is recruited to these 
membrane domains via a Cbp/PAG protein. This protein when phosphorylated on 
a specific tyrosine residue, binds the SH2 domain of Csk and thereby elevates the 
affinity of Csk for Lyn and phosphorylates the negative regulatory 
phosphotyrosine located near the C-terminus of Lyn (Takeuchi et al., 2000). Lyn 
activation requires dephosphorylation of the C-terminal tyrosine Tyr
508
 which 
releases the auto-inhibitory configuration of the kinase domain. Lyn then trans-
auto-phosphorylates Tyr
397
 within its activation loop to generate a highly active 
enzyme. Csk and Cbp/PAG protein regulates this cycle of activation /inactivation 
(Xu et al., 1999). In this work using PEP deficient BMMC and the Lyp/PEP 
inhibitor L75N04, PEP was shown to be a phosphatase that overcomes the negative 
regulation of Lyn brought about by Csk, by dephosphorylating Cbp/PAG.  
This is based on the results of lipid rafts fractionation studies wherein Csk was 
found to be present at higher proportion in raft/detergent insoluble fractions of 
PEP-/- BMMC as well in PEP+/+ BMMC treated with 20μM L75N04 inhibitor. 
Increase in Csk protein level in the rafts fraction was due to the hyper-
phosphorylation of Cbp/PAG protein observed in PEP deficient BMMC and wild-
type treated with PEP inhibitor. In-vitro kinase assay results showed reduced Lyn 
PTK activity in these BMMC. This reduced PTK activity is due to an increase in 
the phosphorylation of Lyn at Tyr
508
 in PEP-/- BMMC and L75N04 treated Pep+/+ 
BMMC which is known to promote an intra-molecular rearrangement whereby the 
SH2 domain of Lyn binds to the phosphotyrosine and occludes the activation 
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domain of Lyn thereby generating an inactive kinase confirmation (Ingley, 2012). 
These results show that PEP regulates Cbp/PAG recruitment of Csk in IgE 
mediated pathway. 
After aggregation of FcεRI receptor, Lyn-mediated signaling pathway leads to 
phosphorylation of numerous substrates including PLSCR1, phospholipid-
scramblase and adaptor molecule LAT(Amir-Moazami et al., 2008).   
PLSCR1 is known to be constitutively associated with Lyn in RBL-2H3 mast cells. 
PLSCR1 knockdown studies in RBL-2H3 shows impaired degranulation and 
suggested a role of PLSCR1 as an amplifier of LAT/PLCγ1/calcium axis (Amir-
Moazami et al., 2008).  
The work presented here shows a lower tyrosine phosphorylation of PLSCR1 in 
PEP deficient BMMC when compared to wild-type BMMC. As PLSCR1 is a 
downstream target of Lyn its reduced phosphorylation is likely a reflection of the 
reduced PTK activity of Lyn.  
Lyn dependent LAT phosphorylation is essential for calcium release from 
intracellular stores that eventually induces calcium influx. This is in agreement 
with the finding that LAT deficiency in  mice leads to  decreased mast cell 
degranulation and cytokine release (Saitoh et al., 2000). Mutation studies in 
BMMC have revealed the importance of phosphorylation of four distal tyrosine 
residues for LAT-dependent downstream signaling. One of these residues, Tyr
136
 
has been shown to be  important for  PLCγ-binding (Saitoh et al., 2003).  
Consistent with this finding, tyrosine phosphorylation of LAT in this study in PEP 
deficient BMMC showed a lower phosphorylation at Tyr
136
 than wild-type. The 
finding explains the previously reported reduced phosphorylation of PLCγ1 and 
decreased calcium mobilization in PEP deficient BMMC (Obiri et al., 2011).  
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The other LAT tyrosine residue investigated in this study was Tyr
195
. This site 
along with Tyr
175
 has been reported by Saitoh et al., 2003 to be involved in Grb-2 
binding and thereby activation of the Ras-Erk signaling pathway. Results from the 
study reported here revealed no change in the phosphorylation of the Tyr
195
 residue 
in PEP-/- and PEP+/+ BMMC which is in agreement with the previous finding 
where no change in Erk phosphorylation was detected between wild-type and PEP 
deficient BMMC (Obiri et al., 2011).  
These findings reveal that, signaling events downstream of LAT is dependent on 
which tyrosine residues are being phosphorylated. PEP deficiency seems to affect 
the Lyn-mediated phosphorylation of PLCγ1 binding site in LAT, resulting in 
significantly reduced calcium mobilization. Hence PEP modulates the 
LAT/PLCγ1/Ca
2+
 axis by positively regulating Lyn activation. 
 
 
4.2 PEP deficiency affects the activation of NFAT transcription factor 
 
NFAT is a transcriptional activator that has previously been shown to translocate 
to the nucleus upon allergen stimulation of IgE-primed cells (Pandey et al., 2004). 
The NFAT transcription factor is made up of a family of five that comprises the 
four genuine members NFATc1, NFATc2, NFATc3, and NFATc4, as well as a 
distantly related NFAT5 (Ton EBP). With the exception of NFAT5, which is 
ubiquitously expressed and activated in response to osmotic stress, nuclear 
translocation and activation of NFAT proteins is induced by the Ca
2+
-calmodulin 
dependent phosphatase calcineurin (Macian, 2005). All NFAT proteins have a 
highly conserved DNA-binding domain that is structurally related to the DNA-
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binding domain of the REL-family transcription factors. This REL-homology 
region (RHR) is the unifying characteristic of NFAT proteins and confers a 
common DNA-binding specificity (Rao et al., 1997). Expression of multiple 
members of the NFAT family such as NFATc1, NFATc2 and NFATc3 in mast 
cells has already been reported wherein they are known to regulate the cytokine 
gene expression (Hock and Brown, 2003; Hutchinson and McCloskey, 1995). 
 
The distinguishing feature of NFAT is its regulation by Ca
2+
 and the 
Ca
2+/
calmodulin-dependent serine phosphatase calcineurin. IgE-FcεRI receptor 
ligation leads to the activation of phospholipase Cγ1 (PLCγ1), which results in the 
release of inositol-1, 4, 5-trisphosphate (InsP3) and a transient release of calcium 
from intracellular stores through the binding of InsP3 to its receptors (IP3 
receptor). This initial release of Ca
2+
 is not sufficient to activate NFAT target 
genes, rather an influx of Ca
2+
 through specialized calcium-release-activated 
calcium (CRAC) channels in the plasma membrane is required (Putney and Bird, 
1993) such that increased levels of intracellular calcium are maintained. Calcium 
binds calmodulin, which in turn activates the calmodulin dependent phosphatase 
calcineurin. NFAT proteins are phosphorylated and reside in the cytoplasm in 
resting cells; upon stimulation, they are dephosphorylated by calcineurin, 
translocate to the nucleus, and become transcriptionally active, thus providing a 
direct link between intracellular Ca
2+ 
signaling and NFAT-mediated gene 
transcription.  
 
In this study, experimental results from NFAT activation studies using luciferase 
assay revealed that PEP deficient BMMC and the L75N04 treated BMMC have 
significantly reduced activation of NFAT transcription factor. Reconstitution 
experiment confirmed the direct role of PEP in the activation of NFAT 
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transcription factor as the activation level in DNP stimulated PEP-/- BMMC 
transfected with PEP expression vector was restored to the level of empty-vector 
transfected, DNP stimulated wild-type BMMC. No impairment in the activity NF-
κB or AP-1 transcription factors was observed in PEP-/- compared to PEP+/+ 
BMMC. Wild-type, PEP knockout and L75N04 treated BMMC showed similar 
activation of these transcription factors. Among these transcription factors only 
NFAT transcription factor activation, is known to be totally dependent on optimal 
calcium release, hence it is logical to predict that all gene expression dependent on 
calcium will be impaired in the PEP-/- BMMC. IL-6 expression is reduced 
following IgE crosslinking in PEP-/- BMMC compared to PEP+/+ BMMC which 
could be attributed to the reduced level of calcium release as the expression as well 
as release of this interleukin is dependent on calcium (Klein et al., 2006; Tanaka et 
al., 2005). 
 
Studies in T-cells have shown that NFAT activation requires dephosphorylation of 
the serine residues in a conserved ∼300-amino acid region located N-terminal to 
the DNA-binding domain termed the NFAT regulatory domain. This domain is 
heavily phosphorylated in resting cells, with the phosphorylated residues (serines) 
distributed in the SP (serine-proline rich) repeats and in the SRR (serine rich 
regions) repeats (Beals et al., 1997a; Okamura et al., 2000). Phosphoserines within 
these regions appear to mask the nuclear localization sequence (NLS) of NFAT. 
Dephosphorylation by calcineurin exposes the NLS and leads to rapid nuclear 
import (Beals et al., 1997a).  
 
Interaction of calcineurin with NFAT is shown to be mediated by a targeting 
domain PxIxIT motif (Proline-x-Isoleucine-x-Isoleucine-Threonine) that is present 
in the NH2-terminal region of the NFAT transcription factor (Aramburu et al., 
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1998; Chow et al., 1999). Removal of five phosphates from a conserved serine-rich 
sequence located immediately adjacent to the PxIxIT calcineurin-binding motif 
exposes the NLS in the regulatory domain and renders additional eight 
phosphoserine residues in the regulatory domain significantly more accessible to 
calcineurin (Okamura et al., 2000). Complete dephosphorylation of all 13 residues 
further results in masking of a nuclear export signal (NES) and promotes the full 
translocation of NFATc1 to the nucleus. Extensive dephosphorylation is necessary 
to fully activate the DNA-binding and transcriptional functions of NFAT. 
 
The calcineurin mediated dephosphorylation and nuclear translocation of NFAT 
are counteracted by NFAT kinases, several kinases have been reported to 
phosphorylate NFAT proteins and control their nuclear shuttling. These include 
glycogen-synthase kinase 3 (GSK3), casein kinase1 (CK1) and JUN-N-terminal 
kinase (JNK). These kinases are distinguished as maintenance kinases which act in 
the cytosol to keep NFAT proteins in a fully phosphorylated state and prevent their 
translocation into the nucleus in resting cells. They also function as export kinases 
to rephosphorylate NFAT in the nucleus and promote its nuclear export, thereby 
stopping NFAT-mediated transcription after mast cell stimulation is withdrawn and 
calcineurin activity declines. 
CK1 docks at a conserved motif that is near the N terminus of NFAT proteins, and 
it functions both as a maintenance and an export kinase by dephosphorylating 
serines present in the SRR motif (Okamura et al., 2004; Zhu et al., 1998).  GSK3 
functions as an export kinase by phosphorylating the conserved SPxx repeat motifs 
present in the regulatory domain of NFATc1 (Beals et al., 1997b). Thus these two 
kinases phosphorylate exactly those residues which are dephosphorylated by 
calcineurin.  
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) in the PxIxIT calcineurin targeting motif of NFATc1, thus 
inhibiting the NFATc1-calcineurin interaction required for the regulation of both 
nuclear accumulation and transcription activity (Chow et al., 2000). In line with 
these published reports, the massive down-regulation of NFAT activity in PEP-/- 
BMMC could be a result of one of the NFAT kinase.  
 
In this work, the observed significant reduction in NFAT activation in PEP 
deficient BMMC and L75N04 treated wild-type BMMC may not only be due to a 
decrease in calcium release but also due to increased activation of NFAT kinases. 
Indeed an enhanced and sustained phosphorylation of JNK in PEP knock out and 
inhibitor treated BMMC was observed. This increased activation of JNK results in 
a reduced NFAT activity is shown in transfection experiments in which the 
dominant negative kinase deficient mutants are able to rescue the effect and induce 
NFAT activation. The increase JNK phosphorylation correlated with an increase in 




, two of the phosphorylation sites 
known to inhibit nuclear translocation of NFATc1. Additionally nuclear 
fractionation studies carried on the wild-type and PEP deficient and L75N04 
treated BMMC shows that nuclear accumulation is inhibited in the absence of PEP.  
 
These findings show that two different processes (a) a down-regulation of the 
PLCγ1/calcium dependent pathway and (b) an increase in MAPK-JNK activation 
pathway regulate the NFAT transcription factor activation in BMMC from PEP 
deficient mice.  
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4.3 Cytokine and Chemokine gene expression is differentially regulated by 
PEP 
 
Affymetrix gene chip analysis was used to determine the genome-wide effect of 
the absence of PEP on RNA transcript. Comparison of gene expression profile 
induced by IgE/DNP stimulation in the presence and absence of PEP showed a 
strong influence of PEP on IgE induced genes.  
 
Gene set enrichment analysis revealed that major class of genes with potential 
function in inflammatory response, calcium-NFAT signaling as well as cytokine 
release were up-regulated in wild-type BMMC whereas in PEP knock out BMMC, 
gene pool with functions in microtubule formation, actin polymerization were up-
regulated when stimulated with IgE/DNP. This effect might be due to the reduced 
calcium/NFAT activation which is required for the inflammatory response. 
 
The microarray analysis also show that the genes involved in calcium/NFAT 
signaling pathway as well as certain cytokine/chemokines genes were down-
regulated in PEP-/- BMMC. To confirm this realtime PCR was conducted, studies 
from this experiment confirmed that indeed the expression of genes coding for 
NFATc1 and PPP3cb (calcineurin) are significantly reduced in PEP knockout as 
well as in L75-N04 treated BMMC which provides mechanistic explanation for 
decreased activation of NFAT. Also expression of IP3R gene (inositol-3-phosphate 
receptor) is significantly reduced in absence of PEP due to the reduced expression 
of PLSCR1 gene (phospholipid scramblase) which is known to activate the 
transcription of the IP3 receptor 1 gene which regulates the intracellular release of 
endoplasmic reticulum calcium stores in response to the second messenger 
inositol-3-phosphate and thus play central role in calcium release(Ben-Efraim et 
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al., 2004; Zhou et al., 2005). Expression of genes that encode protein involved in 
opening of CRAC channels like STIM1 and Orai1 (Fahrner et al., 2009) are also 
down-regulated in PEP deficient and L75N04 treated BMMC. These findings 
explain the reduced calcium mobilization in these BMMC. 
      
It is well established that NFAT and calcium regulates the expression of many 
cytokines and chemokines. NFAT is known to regulate cytokine TNFα, IL-13 
(Monticelli et al., 2004; Yang et al., 2009) and the promoter activity of cytokines 
IL-2 and IL-4 is regulated by NFAT while IL-6 is dependent on calcium. 
Microarray analysis as well as RT-PCR results reveal that the expression of these 
cytokines are drastically reduced in the absence of PEP and suggest that decrease 
in NFAT and calcium levels may contribute to a mechanism for decreased 
cytokine.  
 
Intriguingly, cytokines IL-1β, IL-10 and chemokines like MCP-1 did not show any 
difference in their expression pattern between the wild-type and PEP deficient or 
L75N04 treated BMMC. The plausible explanation for this observation is the fact 
that cytokines are regulated through different pathway and not through 
PLCγ/calcium/NFAT pathway (Akdis et al., 2011).  
 
IL-1β expression is regulated by NF-κB (Hiscott et al., 1993). This can be 
explained by the fact that the activation of this transcription factor remains 
unaffected by the absence of PEP. IL-10 and MCP-1(CCL-2) are regulated by the 
JAK-STAT pathway (Akdis et al., 2011) and NF-κB-ERK pathway (Thompson 
and Van Eldik, 2009).  
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Experimental studies carried out in this work shows that absence of PEP does not 
have any effect on the MAPK kinase-ERK and p38 pathway (Obiri et al., 2011), 
moreover phosphorylation studies of LAT reveal that phosphorylation at Tyr
195 
remains unaffected which is needed for Grb2 binding and thereby ERK activation. 
This might be an explanation for the lack of effect of PEP ablation on MCP-1. 
Additionally mutation studies in LAT have shown that MCP-1 expression is less 
affected by Y136F mutation indicating this site is not essential for MCP-1 
activation (Saitoh et al., 2003). 
 
Hence, absence of PEP affects only those cytokines and chemokines which are 
directly or indirectly dependent on calcium/NFAT signaling pathway.  
 
4.4 PEP deficiency impairs mast cell degranulation and passive systemic 
anaphylaxis in mice. 
 
The key contribution of mast cells to anaphylactic reaction has been widely 
demonstrated. For example; anti-IgE antibody induced mast cell degranulation is 
involved in anaphylactic reactions that result in cardiopulmonary changes and 
mortality in mice (Martin et al., 1989). Functional elimination of certain effector 
molecules like LAT (Saitoh et al., 2000), Btk (Hata et al., 1998) and Vav (Manetz 
et al., 2001) causes diminished responses in mast cell mediated anaphylaxis. 
However, only limited number of phosphatases in FcεRI signaling has been shown 
to be involved in the anaphylactic response. For example, knock out of DUSP2 
(dual specificity phosphatase 2) (Jeffrey et al., 2006) shows reduced susceptibility 
to anaphylaxis. In this study PEP has been demonstrated as important factor in 
antigen mediated degranulation and passive systemic anaphylaxis. The reduced 
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anaphylactic and degranulation response is likely a direct consequence of impaired 
FcεRI signaling observed in PEP deficient BMMC. 
In order to investigate the impact of PEP gene deletion as well as its inhibition of 
enzymatic activity on the capacity of mast cells to degranulate and thereby trigger 
anaphylaxis, was assessed in vitro by measuring the amount of β-hexosaminidase 
released.  
 
Degranulation was impaired in PEP knock out and L75N04 treated BMMC, and 
this impairment was restored by reconstituting PEP in the PEP deficient BMMC. 
IgE-mediated signaling pathway in PEP deficient and L75N04 treated BMMC 
show impairment at receptor proximal event where increased phosphorylation of 
Cbp/PAG and thereby increased recruitment of Csk is observed. This possibly 
contributes to the reduced mast cell degranulation response as Cbp/PAG 
overexpression studies in RBL-2H3 cells have shown reduced degranulation and 
calcium mobilization in these cells (Ohtake et al., 2002a). Additionally functional 
mutation studies on LAT have shown that mice expressing Y136F mutation (the 
site which is essential for PLCγ binding) exhibit reduced serum histamine level, 
demonstrating the critical function of LAT Y-136 residue in vivo (Saitoh et al., 
2003). The functional experiments carried out in this study further support the 
importance of this tyrosine residue LAT, since reduced phosphorylation of Y136 in 
PEP deficient BMMC is correlated with reduced degranulation. Moreover the 
reconstitution experiments restored the degranulation level in these BMMC which 
shows the importance of PEP in the degranulation process. 
 
SCF(stem cell factor), although primarily required for the growth, differentiation 
and survival of mast cells, also potentiates the secretory responses elicited via the 
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FcεRI receptor (Bischoff and Dahinden, 1992). SCF not only enhances antigen 
mediated release of mediators but can itself stimulate degranulation, synthesis of 
inflammatory lipids when added to KL-deprived mast cells (Gibbs et al., 1997; 
Taylor et al., 1995). 
As synergistic interaction exists between SCF-Kit and IgE-FcεRI in the release of 
inflammatory mediators due to the overlapping of signaling pathways, effect of 
PEP deficiency on this signaling pathway was investigated by performing 
degranulation assay on BMMC stimulated with SCF. 
In the work presented here, BMMC also responded to SCF stimulation, the wild-
type BMMC show 80% degranulation when stimulated with 400ng/ml SCF, while 
only 25 % degranulation is seen in PEP knock-out BMMC, to investigate whether 
this difference is due to the absence of PEP, wild-type BMMC were treated with 
L75N04 inhibitor and as expected, L75N04 treated BMMC showed lower 
degranulation (30%) in comparison to wild-type BMMC. This decrease in 
degranulation in the absence of PEP suggests that PEP has a role to play in 
downstream signaling events that lead to degranulation in mast cells. 
Anaphylaxis is controlled by rapid lipid mediator release, degranulation and by 
pro-inflammatory cytokine synthesis in mast cells (Peavy and Metcalfe, 2008).  
Decrease in degranulation as well as in the release of pro-inflammatory cytokines 
explains the observed impairment of systemic anaphylactic response analyzed by 
the fall in body temperature after antigen stimulation in PEP deficient mice and 
L75N04 and C28 treated mice. L75N04 compound turns out to be a potent 
inhibitor than C28 in inhibiting anaphylaxis.  
Taken together,these results show that L75N04 is capable of down-regulating 
calcium mediated transcription and degranulation in mast cells and inhibiting 
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anaphylaxis in mice. The results reported here are quite encouraging for further 
studies to be performed with higher concentrations of L75N04.  
The current treatment for anaphylactic shock is norepinephrine followed 
immediately by glucocorticoids and H1-antihistamine, despite a lack of evidence to 
support these treatments (Choo et al., 2010). Our present finding on L75N04 
provide great hopes for a compound with tremendous potential for the rapid 
treatment of anaphylactic shock that is supported by above experimental evidence. 
Ultimately, one of the major goals of animal model based cell signaling research is 
to provide insight into how biological system in human works, so that novel 
therapeutics may be designed to manipulate signaling pathways to treat human 
diseases. Thus, it is important to verify that the results obtained in the murine mast 
cell system are transferable to human mast cells. LAD2 human mast cell leukemia 
cell line could be a useful tool in future experiments to verify the results that were 
obtained in the BMMC model as well as to test the potency of L75N04 on these 
cell lines.  
These investigations will allow for the observations produced by this study to be 
included in the considerations behind designing strategies for the manipulation of 




The present study provides an insight into the molecular mechanism involved in 
the positive regulation of antigen mediated systemic anaphylaxis by PEP in 
mice.The data presented here identifies PEP to function at receptor-proximal level 
in the IgE-FcεRI signaling pathway.  
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In wildtype BMMC under resting conditions PEP is constitutively associated with 
Csk (negative regulator of Src-like kinases) in the cytoplasm  as shown in Fig 4.A. 
After antigen stimulation, it gets recruited alongwith Csk to the lipid rafts,where it 
functions as Cbp/PAG phosphatase and  thereby inhibits further recruitment of 
Csk. This inhibition leads to positive regulation of tyrosine kinase activity of 
Lyn,which  leads to phosphorylation of downstream  signaling molecules like LAT 
and PLCγ1 that results in calcium mobilization. This increase in calcium influx 
results in the activation of NFAT-transcription factor which ultimately leads to 
degranulation and cyotkine release which culminates in  anaphylactic response 
(Fig 4A).  
On the other hand, in PEP knockout (Fig 4B) and in L75N04 treated BMMC (Fig 
4C), Csk is constitutively present in the lipid rafts since Cbp/PAG in these BMMC 
are phosphorylated under resting conditions. Antigen stimulation leads to higher 
recruitment of Csk to the lipid rafts causing greater negative regulation of Lyn 
which leads to reduced phosphorylation of downstream signaling molecules and 
thereby calcium mobilization and the downstream events are drastically affected 
which is reflected in the reduced susceptibility of PEP knock-out and L75N04 
treated mice to systemic anaphylaxis.  
Thus from, these studies it emerges that PEP is indeed a positive regulator of IgE-
mediated mast cell signaling and seems to be a potential therapeutic target  for 
autoimmune disorders with L75N04 compound  being a starting  point for the 
development of clinically useful PTP inhibitors 
 
 





Fig 4 IgE-mediated FcεRI signaling pathway is positively regulated by PEP (A) In wild-type 
BMMC, PEP-Csk complex is recruited to lipid rafts after stimulation wherein PEP functions as Cbp/PAG 
phosphatase and Csk as negative regulator of Lyn. Dephosphorylation of Cbp/PAG by PEP inhibits further 
recruitment of Csk as a result Lyn gets activated and phosphorylates downstream signaling molecule LAT which 
results in the binding and activation of PLCγ1 which further leads to increase in calcium mobilization, NFAT 
activation, degranulation as a result, wild-type mice are susceptible to anaphylaxis. On the other side in (B) PEP 
knock-out BMMC and in (C) L75N04 treated wild-type BMMC, Cbp/PAG is already phosphorylated and 
recruitment of Csk to the lipid rafts is enhanced and this leads to increased negative regulation of Lyn which results 
in the inactivation of Lyn and thereby downstream signaling molecules are affected leading to reduced calcium 
mobilization is causing inactivation of NFAT and thereby downstream events like degranulation and cytokine 
production are affected, as a result PEP knock-out mice are less susceptible to anaphylaxis. PEP mediated repression 
of recruitment of Csk may account for the described activation of the mast cell signaling
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